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ABSTRACT
Physically or externally stimulated nanostructures often employ multimodality and show encouraging results at preclinical stage in cancer
therapy. Specially designed smart nanostructures such as hybrid nanostructures are responsive to external physical stimuli such as light,
magnetic ﬁeld, electric, ultrasound, radio frequency, X-ray, etc. These physically responsive nanostructures have been widely explored as
nonconventional innovative “nanotheranostics” in cancer therapies. Physically stimulated (particularly magnetic and light) nanotheranostics
provide a unique combination of important properties to address key challenges in modern cancer therapy: (i) an active tumor targeting
mechanism of therapeutic drugs driven by a physical force rather than passive antibody matching, (ii) an externally/remotely controlled
drugs on-demand release mechanism, and (iii) a capability for advanced image guided tumor therapy and therapy monitoring. Although pri-
marily addressed to the scientiﬁc community, this review offers valuable and accessible information for a wide range of readers interested in
the current technological progress with direct relevance to the physics, chemistry, biomedical ﬁeld, and theranostics. We herein cover mag-
netic and light-triggered modalities currently being developed for nonconventional cancer treatments. The physical basis of each modality is
explained; so readers with a physics or, materials science background can easily grasp new developments in this ﬁeld.
Published under license by AIP Publishing. https://doi.org/10.1063/1.5049467
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NOMENCLATURE
AMF Applied magnetic ﬁeld
BBB Blood-brain barrier
CT Computed tomography
EMF Electromagnetic ﬁeld
EPR Enhanced permeability and retention effect
GNRs Gold nanorods
HNCs Hybrid nanostructures
IONPs Iron oxide nanoparticles
LED Light emitting diode
MF Magnetic ﬁeld
MFH Magnetic ﬂuid hyperthermia
MH Magnetic hyperthermia
MNPs Magnetic nanoparticles
MPI Magnetic particle imaging
MRI Magnetic resonance imaging
NIR Near infrared
NPs Nanoparticles
PDT Photodynamic therapy
PS Photosensitizer
PSs Photosensitizers
PTAs Photothermal transduction agents
PTT Photothermal therapy
RF Radiofrequency
SAR Speciﬁc absorption rate
SPIONs Superparamagnetic iron oxide nanoparticles
SPMNPs Superparamagnetic nanoparticles
TER Thermal enhancement ratio
TPE Two-photon excitation
UV Ultraviolet
Vis Visible
I. INTRODUCTION
Current cancer therapies usually lack the focus to provide speciﬁc
therapeutic drug delivery to only the tumor, and it remains one of the
greatest challenges in cancer therapy. Chemotherapy and radiotherapy
are the main pillars of conventional cancer therapies for almost all
types of cancers. However, advancement in both therapies have not
resulted in patient survival rates beyond 30%.1 These therapies also
have several limitations such as severe toxic side effects on patient’s
health, for example, damage to immune systems.2,3 Continuous doses
of chemotherapeutic drugs to a tumor induce drug resistance (chemo-
resistance) mechanisms in cancer cells, and this ultimately results in
the failure of chemotherapy. Development of next generation cancer
therapies has thus been a vital need for a better outcome of a patient’s
health. Among many nonconventional cancer therapeutic strategies
being interrogated in the last decade, therapies that are responsive to
external physical stimuli are of particular interest and can have an
advantage over conventional therapies. Researchers across the globe
invent novel ways to utilize nanoscale agents that are capable of
responding to physical stimulus such as (i) light, (ii) magnetic ﬁeld
(MF), (iii) ultrasound, (iv) radio frequency, and (v) X-ray. Specially
designed nanostructures termed hybrid nanostructures (HNCs) are
highly sensitive to physical stimulus and can perform “on-demand”
cancer theranostics (therapyþ diagnostics).4 The term “theranostics”
symbolizes a new class of treatment options that are capable of provid-
ing both therapy and diagnostics to patients.5
Taking advantage of the interesting physical properties of differ-
ent nanomaterials, especially HNCs, a variety of different physical
stimuli theranostics strategies have been exploited as next generation
cancer therapeutics.5 Chemotherapy and radiotherapy usually lead to
adverse side effects. Theranostics (therapyþ diagnostics) coupled with
engineering means nanotechnological and biochemical approaches
(nanotheranostics), offering various prospects for therapy and diag-
nostics of cancer without any adverse side effects. Physically stimulated
nanotheranostics could destroy cancer tissues/tumors only under spe-
ciﬁc external stimuli and thus could offer fewer side effects with
enhanced treatment speciﬁcity. Additionally, physically responsive
nanomedicine can also be combined with other conventional cancer
treatments such as chemotherapy to achieve synergistic anticancer
effects via different diverse biochemical and physical mechanisms. Use
of externally applied physical stimuli such as magnetic or light signals
in the form of physical forces along with administered signaling mole-
cules, i.e., HNCs, could allow for chemotherapeutic drug presentation
at the right time and at the right dose; this is the main requisite of
cancer therapy.
Nanotheranostics usually refers to integrating imaging and ther-
apy functions of nanoscale materials or nanoagents within a single
modality.6 On the other hand, theranostic, which refers to therapy and
diagnosis of the disease, has been an amazingly popular concept in
recent years, especially in cancer. Researchers and oncologists believe
that the integration of diagnosis and therapy in single modality would
offer a real advantage over independently conducted diagnosis and
therapy.7 The physically stimulated (light/magnetic) nanotheranostics
initiates a cascade of events in the tumor due to the external physical
force (magnetic) or trigger (light), which, in turn, could be employed
for diagnostic imaging, therapy, or both, simultaneously.8 This unique
approach offers superior spatiotemporal control of acquisition features
and nanoprobe monitor of the disease. Most of the HNCs are being
used as an intrinsic stimuli-responsive system whether they react to
endogenous or exogenous in vivo stimuli such as pH,9 enzymes,10,11
redox,12,13 or hypoxia14,15 of the cell/tumor microenvironment. These
in vivo stimuli are restricted to inside the body/organism system, with
the tumor microenvironment, and the use of stimuli can result in an
uncontrolled release of the chemotherapeutic payload. It is anticipated
that these drawbacks could potentially be overcome by using HNCs in
combination with magnetic and light activated remote triggering.
Though numerous examples of physically stimulated HNC nano-
theranostics based cancer therapeutic interventions exist, our motiva-
tion and rationale for suggesting this review was to argue that with the
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rapid development of magnetic and light stimulated nanotheranostics
for next generation cancer therapy applications. Recent progress in
developing newer smart nanostructures has indeed shed new light and
prospect on nonconventional cancer theranostics due to unique physi-
cochemical properties of these nanostructures. While the potential of
intrinsic or biochemical stimuli-responsive nanotheranostics to capi-
talize delivery properties of chemotherapeutics for cancer treatment is
widely documented,16–20 in contrast, magnetic and light stimulated
nanotheranostics and their biomedical applications in cancer therapy
remain relatively contemporary. Concerning cancer, nanotheranostics
approaches have been developed in the laboratories, with some tech-
nologies successfully translated into the clinical stage. Without being
exhaustive, the objective of this original review was to focus physics of
the nanotheranostics response to magnetic and light stimulations. The
term “physical stimuli” in this review deals with magnetic ﬁeld and
light.
The approach of physical stimulation/triggering is, however,
more diverse and not limited to magnetic and light triggering only. As
mentioned above, physical stimulation/triggering encompasses by a
variety of stimuli such as ultrasound, electrical ﬁeld, electromagnetic
ﬁeld (EMF), and magnetoelectric triggering. The advantage of each
triggering modality in the broad ﬁeld of cancer nanomedicine over
conventional cancer treatments has been reviewed recently.21 Among
all these noninvasive and controlled modalities, magnetic and light
stimulations are highly sensitive to external and internal environments
and advancing clinical practices in recent decades. Fortunately, mag-
netic and light triggers have fewer side effects, are easily accessible, and
can be smoothly manipulated for excellent controllability, making
them favorable for cancer theranostics. Thus, the current review is
focused on these two physical stimulation modalities to promote
remarkable advancement of magnetic and light stimulated cancer
nanotheranostics to material scientists, clinicians, oncologists, radiol-
ogists, and patients.
The smart materials or HNCs reviewed here can integrate
“controlled” cancer theranostics into a solitary platform, which is a
revolutionary advancement in the path toward highly safe and effec-
tive personalized cancer therapy.22 We conclude by providing an out-
look on current challenges and opportunities and explore potential
research directions toward accelerating the development and transla-
tion of the physically stimulated nanotheranostics for next generation
cancer therapy.
II. CONCEPT OF PHYSICALLY STIMULATED
NANOTHERANOSTICS
For millions of years, mammals have been improving their
immature and unstable brain activities by physical stimulation. The
established ideal example of such physical stimulation is the mother
and baby; brain activity of the baby can only increase and stabilize
after frequent stimulation by means of physical contact with the
mother. This external physical or mechanical triggering can quickly
stimulate neurons electrically and increase the response in the brain of
young children. Excitingly, in the last few years, a range of physical
stimulation strategies have emerged to treat various human diseases
primarily, cancer4,23 and Alzheimer’s.24,25 Among these and other dis-
eases, physical stimulation has attained moderate advantage for cancer
theranostics in combination with nanomedicine. Achieving adequate
cancer cell targeting and killing with high speciﬁcity while sparing
normal cells, physically stimulation is relying on nanomedicine. In
recent years, nanomedicine combined with radio frequency, X-ray,
and electric ﬁeld are also proposed as novel physical stimulation
strategies.
Although signiﬁcant progress has been attained on internal
“triggers” such as temperature, pH, redox potential, and enzymes,
such a pathological or in vivo stimulation can be executed in a static
passive mode and faces challenges of chemotherapeutic dosage con-
trol, timing, and duration of the therapeutic drug release. Moreover,
the in vivo stimulation approach would not allow for self-regulated
controlled chemotherapeutic cargo release. In the treatment of cancer,
prior drug release kinetics and drug dosing are difﬁcult to predict. To
achieve high therapeutic potential, drug dosing will need to be actively
managed. This could beneﬁt from regulated drug performance made
possible through extraneous control over drug release. The use of
externally applied signals in the form of physical forces along with
administered signaling nanostructures could allow for drug release at
the right time and at the right dose needed for a cancer patient.26
As of today, a broad variety of physical stimulation systems are
engineered and described that are proﬁcient as remotely controlled
theranostics modalities. These systems underlie basic physics princi-
ples and respond to more than one stimulus simultaneously in both
intrinsic and external modes. Physical stimulation strategies coupled
with smart hybrid nanostructures facilitate a desirable way for incor-
porated drug molecule activation. Their on-demand release can be
achieved by local internalization of nanostructures which have high
penetration into cells.18 Biophysical energy such as magnetic ﬁelds,
ultrasound, electric ﬁelds, mechanical forces, and light and tempera-
ture gradients can act as enhancers for nanotheranostics.27 Each form
of physical energy has been associated with a novel technique in cancer
or nanotheranostics. Examples include magnetic ﬁelds for magnetopo-
ration28 and magnetic ﬁeld drug targeting,29 electric current/potential
for electroporation30 and iontophoresis,31 ultrasound for sonodynamic
therapy32 and sonoporation,33 pulsed light for optoporation and drug
release,34 and temperature for thermoporation and hyperthermia ther-
apy.35 The structure of the review is inspired from the rapidly increas-
ing ﬁeld of cancer nanotheranostics and the number of publications
investigating the potential of novel physically stimulated strategies (i)
to enhance remotely controlled and triggered drug delivery to tumor,
(ii) to induce hyperthermia ablation using different types of magnetic
nanoparticles (MNPs), or near infrared (NIR) light induced hyperther-
mia using gold nanorods (GNRs), (iii) to enhance radiotherapy in a
clinical setting and with hybrid nanostructures as theranostic agents
particularly magnetic@gold, silica@silver, carbon@gold, or gadolin-
ium, (iii) to promote a photodynamic effect with multifunctional
hybrid nanostructures, and (iv) to permeate the blood-brain barrier
(BBB) usingMNPs.
As far as physical stimulus or responsive therapies are concerned,
nanotheranostics, however, may have its unique advantage. Unlike
chemotherapy which applies to the whole body, external physical
stimulus-responsive nanotheranostics are often applied locally onto
the tumor.4 Real-time monitoring of chemotherapeutic agents distrib-
uted in the whole body, particularly in the tumor, is essential for maxi-
mal therapeutics outcome. Existent conventional chemotherapeutics
modalities have limited monitoring window during and after the treat-
ment. On the other hand, physically stimulated nanotheranostics, e.g.,
light, magnetic ﬁeld, ultrasound, allows a real monitoring window of
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the distribution of therapeutic agents. Thus, physically stimulated
nanotheranostics applied at the best timing is opening effective thera-
peutic options by combining imaging required to real-time monitor of
tumor when the stimulus-responding nanostructures reach its maxi-
mal level in the tumor after its administration. In addition, nanothera-
nostics coupled with imaging modalities could also be helpful to
monitor the under or over dosed therapeutic responses (e.g., optical
energy, X-ray dose, etc.) under physical stimuli.
III. MAGNETIC-STIMULATED NANOTHERANOSTICS
Every living organism on the planet is under continuous exposure
of the Earth’s natural magnetic ﬁeld (MF). The ﬁrst one is a very slow-
changing (in terms of millennia) quasi-static component with ﬂux den-
sity (BE) 30–60 lT depending on the location on the Earth’s surface.
The second one is represented by comparatively fast ﬂuctuations within
a wide range of frequencies (from fractions of Hz to many kHz) with the
amplitude of BS by 2 or 3 orders of magnitude less than that of BE.
36
During the twentieth century industrial revolution, numerous man-
made technogenic electromagnetic ﬁeld (EMF) sources were added to
the natural ones. These man-made systems such as power lines, electro-
technological industrial machines, telecommunication facilities, con-
sumer electronics, medical equipment, and many others produce high
MF which are much stronger than the natural ones. The map of natural
and technogenic magnetic ﬁelds with their applications and biological
limits is shown in Fig. 1. A revolution in the medical technology
endorsed the use of MF for biomedical applications such as targeted
drug delivery, magnetic hyperthermia, magnetic resonance imaging
(MRI), and many others. A new scientiﬁc division “Magnetobiology”
has been established to study the interaction of magnetic ﬁelds with liv-
ing organisms.37 In general, a magnetic ﬁeld or magnetic energy is non-
invasive in nature compared to high strength electrical ﬁelds. MNPs are
primarily used in drug delivery, magnetic ﬂuid hyperthermia (MFH),
and for magnetic resonance imaging purposes in cancer theranostics.
A. Magnetically guided drug delivery
1. Underlying physics
MNPs can be used as a carrier to deliver drugs through the com-
plex physiological architecture that includes blood, cells, and tight tis-
sue junctions. The interactions of MNPs with tissues can be modest in
the presence of an applied magnetic ﬁeld (AMF) and drag force expe-
rienced by MNPs mostly due to the blood ﬂow [Fig. 2(a)]. Trajectory
of the MNPs conjugated with drug molecules inside the body directed
by an external magnetic ﬁeld is represented by the equation27
Fm ¼ l0VM:rH; (1)
where V is the volume of the material, l0¼ 4p  107 N/A2 is the
magnetic permeability of vacuum, M is the magnetization (magnetic
dipole moment per unit volume), and H is the applied (auxiliary) MF.
In order to effectively overcome the drag experienced by nanotrajec-
tory in the body, the magnetic force due to the external ﬁeld must be
greater than the inside drag force, and which is given by the equation
F ¼ 6pgrhv; (2)
where g is the viscosity of blood, rh is the hydrodynamic radius of the
particle, and v is the velocity of the particles.
With the characteristics of driven magnetic accuracy, MF can be
modulated externally in order to control the motion of nanotrajectory
for high drug-carrying capacity and synchronized targeted drug
release. Magnetically driven drug delivery platforms can therefore
have lower toxicity and enhanced therapeutic effects. In principle,
magnetic targeting and stimulation in nanomedicine consist of the
FIG. 1. The map of natural and technogenic magnetic ﬁelds currently used in medical sciences. Reproduced with permission from Golovin et al., J. Nanopart. Res. 19, 63
(2017). Copyright 2017 Springer ScienceþBusiness Media Dordrecht.36
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following steps: (i) coupling the therapeutic drug to the MNPs; (ii)
applying an extracorporeal static MF to drag MNPs to the tumor or
desired location; and (iii) the magnetically inﬂuenced drug release
from the MNPs at a speciﬁc anatomic site under the extracorporeal
alternating magnetic ﬁeld (AMF). Extracorporeal static or dynamic
magnetic ﬁelds can be positioned to improve the deposition of injected
magnetically responsive drug carriers at tumor site, a process termed
magnetic guidance. Physical basis of MNP-based drug delivery system
to targeted anatomical site such as a cancerous tumor is schematically
represented in Fig. 2(b). The typical setup for studying an in vitro
AMF-triggered drug release from iron oxide nanoparticles (IONPs) is
shown in Fig. 2(c). Researchers constructed a high power current gen-
erator feeding an application coil of sufﬁcient diameter to hold the
drug conjugated IONP carrier sample (1–5ml).38
The efﬁciency of the magnetic guidance is dependent on the ﬁeld
effect expressed by MNPs under the force exerted on them by the
EMF. The force acting on a single MNP exposed to an EMF can be cal-
culated by modifying Eq. (1) and is given by the equation40
Fm ¼ N:m:rB; (3)
where N¼ 1 (if N> 1, the force per an ensemble of N particles may
arise), m is the magnetic dipolar moment, andrB is the spatial gradi-
ent of the magnetic ﬂux density. The fact that the magnetic force on
an MNP cannot take a maximum magnitude within the body (away
from the source of the magnetic ﬁeld) means that where the drug/par-
ticle complex is injected systemically, it is impossible to target regions
deep within the body without targeting some surrounding regions
more strongly.41 This underlying physical phenomenon behind the
drug targeting leads us to conclude that the externally AFM targeted
drug delivery of a nanosystem is appropriate solely for targets close to
the surface of the body. However, within this limitation, such magnetic
force driven tumor targeting would be more effectual compared with
modest passive tumor accumulation of nanoparticles (NPs) relying on
the enhanced permeability and retention effect (EPR) of tumors.
2. Clinical progress
Inspired by the novel hierarchical design of hybrid nanostruc-
tures (HNCs) and their response to magnetic forces, diverse stimuli-
responsive functional nanomaterials have been reported for drug
delivery, involving various architectures and surface functionalities
that respond to changes in magnetic ﬁelds.42–45 In a few studies, it has
been shown that the local temperature rise due to transformation of
electromagnetic energy into heat (magnetothermal response) is used
to trigger changes in the HNCs without a need to elevate the tempera-
ture of the entire surrounding system.46–48 Because of the abundant
phenotypic diversity of cancerious tissues and solid tumors, drug tar-
geting via the EPR effect is encountering set backs and only a burst or
“one shot” release may be envisioned in this case, thus limiting the
chemotherapeutic outcome.38 The HNCs coupled with magnetic
remote triggering modality ensure pulsatile spatiotemporal controlled
cargo/drug release several times on demand, with control over the dif-
fusion rates and the times of drug release. Using either uniform or
nonuniform MF generated by an electromagnet with remote magnet
positioning has been designed to strigger superparmagnetic nanopar-
ticles (SPMNPs) with a copolymer shell hosting the substrate and a
complementary enzyme for cancer theranostics. These HNCs consist
of biocatalytic enzymes for triggering biocatalytic system to achieve
well-controlled magnetic-ﬁeld-triggered cancer drug release with a low
strength magnetic ﬁeld.48 Although this developed nanosystem is
remotely activated under magnetic ﬁeld, it is lacking the accurate con-
trol of on-demand repetitive drug release and rapid switching between
“on” and “off” states. This has been further resolved by assembling
magnetic-driven drug delivery device called a “microspouter.” This
consists of a polydimethylsiloxane (PDMS) reservoir, a thin mem-
brane, and a magnetic sponge.49 Different from EPR drug targeting
and release (diffusion-based) mechanism, the microspouter is driven
by the magnetic sponge and can perform on-demand drug release
instantaneously through a spouting triggered by external magnetic
ﬁelds, in vitro and ex vivo. Distinct from targeted drug delivery,
FIG. 2. (a) Schematic illustration of brain tumor magnetic targeting following the systemic administration of magnetic nanoparticles. Targeting can presumably be achieved due
to the combination of several phenomena including passive biodistribution of the administered nanoparticles, pathophysiological peculiarities of tumor vasculature, and the prin-
ciples of magnetic entrapment. Reproduced with permission from Chertok et al., J. Controlled Release 122, 315 (2007). Copyright 2007 Elsevier B.V.39 (b) Schematic represen-
tation of an MNP-based drug delivery system to anatomical target site as cancerous tumor. Reproduced with permission from Lakshmanan et al., Adv. Drug Delivery Rev. 71,
98 (2014). Copyright 2014 Elsevier B.V.27 (c) Setup for AFM-triggered model drug release experiment through drug diffusion across semipermeable membrane. 1: Solenoid
and calculated magnetic ﬁeld lines; 2: dialysis bag (e.g., Spectra/Por Float-A-LyzerTM, 50 000 g mol1 molecular weight cut-off (MWCO), 10mm diameter, 5 ml volume); 3: cyl-
inder (50ml) ﬁlled with aqueous buffer. Usually, the drug is titrated in the outer medium, in “sink,” and thermostatic (37 C) conditions. Reproduced with permission from Mertz
et al., Biochim. Biophys. Acta, Gen. Subj. 1861, 1617 (2017). Copyright 2017 Elsevier B.V.38
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controlling the targeting ratio is the essential factor for effective cancer
nanotheranostics. This has been advanced by using magnetotatic bac-
teria as a drug carrier. Magnetotactic bacteria have been used to trans-
port 70 different chemotherapuetic drug-loaded nanoliposomes into
hypoxic regions of a tumor, to attain a high target ratio.50 Each bacte-
rial cell contains a chain of supermagnetic iron-oxide nanocrystals,
and they tend to swim along local magnetic ﬁeld lines and can possess
magnetotaxis directional control toward a tumor. When operating in a
computational algorithm and magnetic environment, this nanoassem-
bly can rival artiﬁcial medical nanorobots/transporters of drugs in the
tumor region with high targeting ratio.
To achive a high yield drug release within the tumor microenvi-
ronment, a variety of nanoformulations have been designed to work in
response to remote magnetic actuation. Liver tumor, for example, has
been targeted with magnetic janus “nanobullets,”51 pancreatic tumor
targeted with magnetic microbubbles,52 colorectel cancer targeted with
magnetic silica core/shell nanovehicles,53 and lung tumor targeted
with hybrid peptide@magnetic nanoassembly,54 all designed as remote
magnetic actuation modalities. Ideal magnetic nanovechicles must sat-
isfy a number of common criteria, speciﬁcally nanovechicles must (i)
avoid in vivo nonspeciﬁc cellular intercations, (ii) faciliate high yield
drug administration at the tumor site away from the site of adminis-
tration, and (iii) enable elimination of nanocompunds from a tumor
after its function as a carrier has been fulﬁlled. There are many ways in
which these requirements could be fulﬁlled. For example, nanomicelle
superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic
drag force can deliver sorafenib drug (a pan tyrosine kinase receptor
inhibitor and the sole chemotherapeutic agent clinically approved for
hepatocellular carcinoma patients) to the tumor for systemic cancer
therapy with high yield.43 On the other hand, magnetic single-walled
carbon nanotubes (SWNTs)55 and superparamagnetic nanomicells56
can improve breast cancer and colorectal cancer immunotherapy,
respectively, via magnetically driven drug delivery. These novel HNCs
are efﬁciently delivering chemotherapeutic cargoes to tumor sites,
while fulﬁlling the criteria stated above.
Instead of relying on conventional MNPs or SPMNPs involved
in drug delivery strategies, the next generation of magnetic nanocap-
sules to treat tumor in a noninvasive way has been proposed (Fig. 3).57
State of the art magnetic nanocapsules are designed to deliver chemo-
therapuetic cargoes with accurate control of the (i) release rate, (ii)
release amount, and (iii) number of doses, in an optimized magnetic
ﬁeld. Despite a number of attempts to magnetically guide drug deliv-
ery, this novel nanocapsule coupled with magnetic actuation resolving
the issue of on-board drug components high yield.
To date, magnetically targeted nanosystems that use passive or
active tumor targeting are lagging behind in clinical trials; all of the
hybrid nanoassemblies currently being tested were only used for tar-
geting or ﬁxation after intravenous administration. The clinical prac-
tice of magnetic targeting is currently restricted by the limited depth of
penetration, which is around 2 cm at present for SPIONs and other
SPMNPs.44 Effective ways to integrate magnetic guidance along with
passive and active targeting are therefore a vital challenge and need to
be addressed. Similarly, there is the potential to explore the utilization
of the hyperthermic effect for treatment and controlled drug release,
and MRI for diagnosis and monitoring. MNP-based nanosystems
have also been studied for MFH and MRI in preclinical trials and are
presented in Sec. III B.
B. Magnetic fluid hyperthermia
1. Underlying physics
Though magnetic drag force has been used for targeting nanocar-
goes to tumor site, their activation or therapy is the ﬁnal step that com-
pletes nanotheranostics after reaching the target. Furthermore, AMF
can also be used to release drugs from nanocarriers such as MNPs, lip-
osomes or nanoemulsions. These nanocarrier can contain SPMNPs
that heat up to temperatures of the order of 42–45 C under the inﬂu-
ence of AMF and release drug to improve the outcome of cancer
nanotheranostics.58,59 SPMNPs have been extensively considered for
remote controlled drug delivery applications where, their response to
FIG. 3. (a) The main components of the proposed magnetic nanocapsule based drug delivery system. A: Ring-shaped external magnetic system, B: drug release module, C:
the robotic capsule, D: complementary modules within the capsule (anchoring mechanism, active locomotion system, and localization and orientation detection module), E:
patient bed, F: clinician, G: joystick, and H: human capsule interface. Point P represents the origin of the general coordinate system XYZ, his taken with respect to the x-axis,
and u is taken with respect to the z-axis. (b) The components of the slider crank mechanism. A: an internal permanent magnet (IPM), B: disk-shaped piston, C: connecting
rod, D: disk, and E: robotic capsule. The coordinate system Xc Yc Zc of the IPM with respect to the general reference system XYZ is shown in (a). Reproduced with permission
from Munoz et al., J. Med. Device 10, 011004 (2015). Copyright 2016 by ASME.57
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static or AMF resulted in enhancement of the entrapped drug release
rate within a tumor. AMF at frequencies typically greater than 10 kHz
has been used to remotely heat SPMNPs, and then, the local thermal
ﬂuctuations within the nanoassembly modulate drug releasing proper-
ties.60 From a physical point of view, the presence of MNPs in an
aqueous or physiological medium (considered as magnetically disor-
dered medium) leads to extremely strong localization of the impact
from the EMF and results in MFH therapy of the tumor. The main
physical phenomenology related to MFH is the conversion of the elec-
tromagnetic energy into heat when MNPs are subjected to AMF. The
last decade has witnessed a signiﬁcant increase in theoretical research
related to MFH with emphasis on SPMNPs. The MFH is a novel
approach that has been tested in vivo, to kill cancer cells in elavated
temperature of the order of 42–45 C without damaging the surround-
ing normal tissues. MFH is a simplistic yet realistic radio-oncology
methodology; however, a-priori estimation of the thermal history in
internal tumors for optimizing a MFH treatment protocol for canceri-
ous tumor is the need of the hour. Numerous review articles and book
chapters have already dealt with the many facets of the physical aspects
of MFH from its ﬁrst phase to clinical transition. In this section, physi-
cal aspects standing in the way of more reliable MFH for clinical stage,
mainly those published within the last few years, are discussed.
Without going into details of the dissipation processes of mag-
netic energy of MNPs and mechanisms of heat generation by these
nanoparticles such as brownian motion, neel relaxation, and hysterysis
loss (schematics outlined in Fig. 4), the current section will outline the
advanced biophysical mechanism of MFH. The physical mechanism
of these processes has been thoroughly described in numerous reviews
including recently in the same journal61–64 and also by our group.65–67
An ideal mechanism for MFH should be noninvasive, speciﬁc to the
tumor cells, and enables precise targeting and localization to the depth
of tumor with utilizing optimum thermal energy. The computational
model of thermal energy dissipation for tumor at the time of MFH
therapy is designed to achieve focused cancer theranostics and is
expressed in the classical Pennes bio heat equation68
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This representative MFH temperature distribution model is tak-
ing care of three-dimensional (3D) tumor anatomy and function of
both space and time T(x, y, z). Qgen is the volumetric heat generating
source under MFH, Qmet is a metabolic heat generation by the physio-
logical systems, and Qb is the heat removal by convective transport
due to blood perfusion. This biophysical temaprature modeling within
tumor ensures further simpliﬁed solution, isotropic thermophysical
properties that are assumed for the tumor system. The average size of
the tumor ranges from millimeter to centimeter, and within this
region, the magnetic ﬂuid is injected, and hence the order of magni-
tude for the effective tumor diameter undergoing MFH is 103. The
thermal conductivity of tumor tissues is 0.6W/mK at room temper-
ature, and the convective heat transfer coefﬁcient due to cooling by the
surrounding body ﬂuid is similar to natural convective effects (heat
transfer coefﬁcient 10W/m2K). Accordingly, the associated Biot
number for the tumor is of the order of 101 which satisﬁes the
requirements of a lumped system modeling. Hence, Eq. (4) underlies
the physics of MFH in tumor through energy balance between the
transient thermal storage by the tumor and the heat generation due to
MFH. Performance of the novel physical and computational predic-
tions of the MFH compared with respect to the clinical trial report on
murine systems by different authors has been validated.68 The compu-
tational model derived for clinical MFH performs appreciably well
with respect to the experimental data and more toward the later stages
of hyperthermia.
FIG. 4. (a) Characteristic relaxation times of the MNP magnetic moments as a function of the magnetic core radius (for Fe3O4). -O0 is the axis of easy magnetization, and li
and l are the magnetic moments of the ith atom and the nanoparticle, respectively. sN and sB stand for the time of Neel’s and Brownian relaxation, accordingly. Exposure time
is the half of the period of the sinusoidal AMF. Reproduced with permission from Golovin et al., J. Nanopart. Res. 19, 63 (2017). Copyright 2017 Springer ScienceþBusiness
Media Dordrecht.36 (b) Illustration of customized 3-D printed multiwelled sample holder with corresponding measured ﬁeld strengths, and a schematic illustration of the mag-
netic hyperthermia measurement setup under gradient magnetic ﬁeld. Reproduced with permission from Bauer et al., Nanoscale 8, 12162 (2016). Copyright 2016 The Royal
Society of Chemistry.69 (c) Schematic representation of magnetic particle imaging (MPI)-guided hyperthermia treatment whereby the signal is generated in the ﬁeld free region.
Reproduced with permission from Abenojar et al., Prog. Nat. Sci.: Mater. Int. 26, 440 (2016). Copyright 2016 Chinese Materials Research Society and Elsevier B.V. T.70
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2. Clinical progress
Interest in MFH has grown immensely since it was ﬁrst used in
veterinary clinic to destroy metastases in lymph nodes in dogs in the
year 1957. Since then, countless efforts have been made to explore the
potential of MNPs in cancer theranostics. In 1993, Jordan et al. directly
delivered MNPs into a tumor for selective heating of tumors and found
a much more effective hyperthermia therapy to kill cancer cells.71
MFH is projected as nonconventional cancer treatment modality based
on the physiological circumstance of tumor cells; usually, cancer cells
possess higher heat sensitivity over normal cells at milder temperatures
bordering 43 C, resulting in damage to tumor cells only.72 Depending
on the treatment modality and location, tumors are typically heated in
the range of 41–46 C (moderate hyperthermia) or >46 C (thermoa-
blation) for a deﬁnite time interval. MNPs can magnetically target at
tumor site following intratumoral, intraperitoneal, intra-arterial (IA),
intracavitary, or intravenous administration (Fig. 5). However, the oral
administration of MNPs is inappropriate as most of the MNPs will be
fecally be excreted, owing to their large size.62
For preclinical or clinical MFH applications, it is crucial to accu-
rately control temperature and magnetic ﬂuid concentrations in and
around the target volume. Tumor temperature rise is mainly depen-
dent on cancer tissue properties such as blood perfusion cooling and
speciﬁc absorption rate (SAR) of homogeneously dispersed MNPs
within the tumor. A recent study showed that a bladder catheter could
be used to inject MNPs into a bladder tumor.74 A. homogeneous dis-
persion of a magnetic nanoﬂuid containing IONPs is injected into a
bladder tumor and monitored using MRI. Uniform power dissipation
within the bladder target was achieved using this novel nanotheranos-
tics technique. A preclinical MFH investigation using a novel small
animal MF applicator on 25 female rats with bladder cancer showed
well-localized heating of the rat bladder lumen with effective control
of temperature in the bladder and minimal heating of surrounding tis-
sues. On the contrary, hybrid engineered magnetic thermo-responsive
iron oxide nanocubes are designed to merge MFH and heat-mediated
drug delivery at preclinical stage.75 This nanotheranostics platform
works under clinical MFH coupled with MRI and at a low iron dosage.
The platform is enabling the translation of MFHmediated chemother-
apy and the ability to monitor tumor progression post-MFH-treat-
ment by MRI, thus overcoming the clinical limitation of MFH. After
promising results in vitro, the nanotherapeutic system must be
assessed in vivo before entering into clinical stage. Several recent stud-
ies reporting in vivo experiments conﬁrm the ability of various hybrid
MNPs/SPMNPs entities to eradicate different tumors such as breast,
liver, colon, etc., completely via MFH.76–79 The MFH modality offers
the unique advantage in brain cancer therapy, as well, in that, it can
noninvasively and remotely induce tumor suppression via mechanical
force of MNPs.80 AFM with low frequencies can penetrate the human
head, without damaging the normal brain tissues and can be operated
in a time selective and spatially constrained manner for remotely trig-
gered nanotheranostics, as the interaction is mediated by the MNPs.81
Next generation HNCs accommodating MNPs inside a liposome
bilayer in a single nanoplatform, termed “magnetoliposomes,” have
recently been introduced into cancer theranostics.82–85 Well-deﬁned
FIG. 5. Next generation MFH therapy coupled with nanotheranostics at clinical stage and modeling of MNP-based hyperthermia therapy: (a) simulated magnetic ﬁeld gener-
ated by a coil applicator; (b) image-based particle density in the liver; (c) induced tissue temperature distribution considering perfusion and major vasculature; (d) resulting abla-
tion as determined using CEM43 thermal dose model. The targeted tumor location is indicated with an arrow. Reproduced with permission from Datta et al., Cancer Treat.
Rev. 50, 217 (2016). Copyright 2016 Elsevier Ltd.73
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temperature kinetics and controlled drug release are mandatory to
improve the efﬁcacy of MFH. Magnetoliposomes can suffer changes in
their assembly and permeability and release their payload in a control-
lable way by partial disruption of the bilayer structure under AFM
pulses or heat produced by MFH. The thermo-responsive behavior of
liposomes is broadly customized close to the clinically relevant hyper-
thermia values. In recent research work, short magnetic pulse
(500 kHz, 20 kA) thermosensitive bilayer-embedded magnetolipo-
somes are proposed to enhance MNPs mechanical motion induced
drug release in the HeLa tumor model and MFH without distressing
normal cells by overheating.86 These novel HNCs combine magnetic
targeting as well as active targeting modality (methotrexate as a surface
ligand for folate receptor-overexpressed cancer cells) with doxorubicin
(DOX) and a ﬂuorescent dye (Cy5.5) for tumor imaging, and achieved
a 100% tumor suppression within 14 days.
In recent years, MFH has been suggested as localized therapy to
heat a speciﬁc region of the body, e.g., a tumor. In order to improve
the effectiveness, MFH has often been evaluated as an adjunct therapy
to enhance chemotherapy and radiotherapy. MFH, for example, can
synergistically enhance the efﬁcacy of numerous chemotherapeutic
drugs including doxorubicin, cisplatin, cyclophosphamide, and bleo-
mycin.62,87,88 Apart from chemotherapy, MFH can also improve
radiotherapy by enhancing the thermal enhancement ratio (TER),
where TER is the ratio of the dose of radiation alone that is required to
achieve the end point to the dose of radiation with heat to achieve the
same end point.89 MFH is believed to boost radiotherapy outcome via
protein denaturation, following inactivation of proteins involved in
DNA repair. In vivo, MFH can increase vascular perfusion and
oxygenation of formerly radio resistant hypoxic areas leading to radio-
therapy success. There have been a number of incremental in vivo pre-
clinical trials in recent years on the impact of MFH on various cancers
in combination with radiotherapy, chemotherapy, or both using vari-
ous HNCs.89–91 This contribution emphasizes the potential utility of
MFH to exploit nonlocalized effects and different approach to avoid
issues with targeting NPs heat deposition, opening the possibility to
explore novel directions for nanotheranostics.92
Although MFH has been integrated into clinical practice to treat
a relatively wide range of cancer types, it is necessary to consider
some clinical fundamentals when locally dealing with solid tumors.
(i) The penetration depth of AMF should be higher, allowing to
reach deeper tumor tissues, (ii) MNPs administration in tumor site
in a wide concentration range and continual throughout the MFH
treatment for repeated therapy sessions, (iii) the heat generated
should be uniform within the tumor microenvironment and it must
be the highest possible at the lowest particles dose, (iv) reliability for
providing a precisely controlled intratumoral heat exposure mediated
by MNPs,64 (v) safety of AMF to human body and vital organs
including high voltages producing eddy currents in physiological
media. Another main concern relates to the safe use of AFM for
whole body or tumor only. Recent reports proposed that to protect
healthy tissue surrounding the tumor against excessive heating, the
product of applied ﬁeld amplitude and frequency (Hf¼C) must be
limited (C 4.85 108 A m1 s1). There are two different
approaches for the application of AMF in the clinic. The ﬁrst is that
the theoretical limit of C 4.85 108 A m1 s1 is for whole-body
exposure. The second is that this criterion will be accordingly weaker
for smaller body regions being under ﬁeld exposure. For instance, a
combination of ﬁeld amplitude of about 10 kA m1 and a frequency
of about 400 kHz (leading to Hf¼ 4 109 A m1 s1) was suggested
for the localized treatment of cancer.93,94
MFH has shown to be a promising approach to overcoming the
barriers encountered by current cancer therapies in the last decade.
Since then, signiﬁcant efforts have gone into the development of clini-
cal MFH trails together with nanotheranostics. The publicly listed
company, MagForce AG based in Germany, has developed different
hybrid nano assemblies such as aminosilane coated ferroﬂuid
(NanoThermV
R
), an AMF applicator device (NanoActivatorV
R
) and
temperature simulation software (NanoPlanV
R
). In recent years, the
company has successfully conducted phase 1 and 2 clinical studies on
glioblastoma and prostate cancer patients using intratumorally deliv-
ered MNPs and the subsequent application of AMF via the home
made MagForce system.62 In a phase 2 clinical trial conducted by
MagForce, patients with recurrent glioblastoma demonstrated a
median overall survival of 13.4months (n¼ 66) from the time of
tumor recurrence. During and after the MFH treatment, treated
patients showed no prolonged side effects other than worsening motor
disturbances, which may be related to disease progression rather than
MFH. In the phase 1 and 2 trials, MagForce is using lower frequencies
of 100 kHz, and the ﬁeld strength of 1.35 109 A m1 s1 to 8.5 108
A m1 s1 for glioblastoma patients, while for patients with prostate
cancer, 5 108 A m1 s1 is used.
C. Magnetic imaging
1. Underlying physics
a. Magnetic resonance imaging. One of the holy grails in cancer
theranostics is to achieve accurate diagnosis and imaging of tumor
boundaries. Multimodal imaging strategies incorporating diverse
images have increased the ability of oncologists to diagnose, guide, and
monitor outcomes of cancer therapy. MRI is an extensively used radio-
logical/biomedical imaging technique in the cancer theranostics and
can facilitate multiparameter anatomical demonstration of diagnosis.95
The development of biomedical instrumentation and the use of con-
trast agents have provided better-quality tumor imaging. However, the
issue of accuracy and false imaging remains a problem.96 MRI is both
ionizing radiation-free and noninvasive and that permits reconstruc-
tion of atomic nuclear magnetization signal into two-/three-dimen-
sional (2D/3D) images. The underlying physical phenomenon of MRI
in clinical translation is to acquire the restored or residual magnetiza-
tion by adjusting parameters in either the longitudinal direction or the
transverse plane (Fig. 6). The longitudinal imaging or spin lattice
relaxation parameter is termed T1-weighted MRI, and transverse or
spin–spin relaxation parameter is termed T2-weighted MRI. Basically,
T1 and T2 images show bright and dark signal contrasts, respectively,
which represent recovered (T1) or residual (T2) magnetization after a
speciﬁc time cycle. Usually, T1 MRI is advantageous for assessing fat
tissue or liquid retaining anatomical assemblies (e.g., joints), which are
challenging by T2 MRI. In contrast, T2 MRI is powerful in assessing
water-rich anatomies, which appear as bright signals in speciﬁed spin-
echo (SE) sequence. SE protocol or arrangements is useful for T1- or
T2-weighted contrasts and helps in creating molecular interplay by
removing effects of exterior magnetic ﬁelds.
The main shortcoming of MRI is that the contrast image gener-
ated is not enough for an accurate tumor diagnosis. Despite the fact
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that the proton density of a tissue is stationary, enhancing the signal
quality or modifying the relaxation time by administering a contrast
agent can alter the magnetic characteristics of nearby water protons.
The signal enhancement due to a contrast agent depends on its longi-
tudinal (r1) or transverse (r2) relaxivities, which are deﬁned as the
increase in relaxation rates R1¼ 1/T1 and R2¼ 1/T2, respectively.97
The use of paramagnetic metal ions as MRI contrast agents has made
a signiﬁcant impact by inﬂuencing the MRI signal properties of sur-
rounding tissues. Gadolinium-based metal oxides are extensively used
as MRI contrast agents in cancer, cardiovascular, and inﬂammation
diseases. SPMNPs present great advantages as T1-T2-weighted contrast
agents over the gadolinium-based oxides as they possess suitable mag-
netic saturation and superparamagnetic properties, which are crucial
for enhancing MRI signals and contrast.
The efﬁcacy of an MRI signal intensity without and with contrast
agent including SPMNPs is evaluated by the following equation:
Ri ¼ 1Ti;0
 
þ riC; (5)
where Ri is the observed relaxation rate (per second); Ti,0 is the relaxa-
tion time before adding the contrast agent (s); ri is the relaxivity coefﬁ-
cient (milli per molar second); and C (millimolar) is the contrast agent
concentration. Superparamagnetic iron oxide nanoparticles (SPIONs)
with diameters of several nanometers, which can be detected by high
magnetic ﬁeld, have also been studied as T1 and T2 contrast agents,
being capable of visualizing individual cancer cells. The high magnetic
susceptibility of SPIONs enables them to be identiﬁed as darker signals
on the MRI images being suitable T2 contrast agents. The T2 relaxivity
for SPIONs is at least 5–10 fold higher than T1 relaxivity. Recently, our
group introduced the primitive concept of dual-mode contrast agents
by making hybrid gadolinium doped SPIONs100,101 for cancer thera-
nostics. According to outer-sphere spin–spin relaxation
FIG. 6. Schematic summary of MRI principle using IONPs. (a) Alignment of spins under applied magnetic ﬁeld B0 and precession under Larmor frequency x0. (b) Spin relaxa-
tion mechanisms of T1 and T2 after applying radio frequency (RF) pulse. (c) Hypothetical graphs of longitudinal and transverse relaxations with time. Reproduced with permis-
sion from Javed et al., J. Nanopart. Res. 19, 366 (2017). Copyright 2017 Springer ScienceþBusiness Media B.V. 2017.98 (d) Illustration of the contrast enhancement of
magnetic nanoparticles. Under an external magnetic ﬁeld, magnetic nanoparticles generate an induced magnetic dipole moment that perturbs the magnetic relaxation of water
protons. Such changes result in signal reduction on T2-weighted MRI and lead to magnetic resonance (MR) contrast enhancement, with darkening of the corresponding section
of the image. Water protons inﬂuenced by magnetic nanoparticles have relatively short T2 relaxation and produce negative contrast enhancement. Reproduced with permission
from Yu et al., Drug Delivery Transl. Res. 2, 3 (2012). Copyright 2011 Controlled Release Society.99
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approximation, the relationship between the magnetization and the T2
relaxation rate (R2) for SPMNPs is described by the equation
102
R2 ¼ 1T2 ¼
256p2c2
405
m2s V 
r2
D 1þ L
r
  ; (6)
where c is the gyromagnetic ratio of the protons, ms is the saturation
magnetization of the MNPs, V is the MNPs volume fraction, r is the
MNPs radius, D is the diffusion coefﬁcient of water molecules, and L
is the thickness of the surface coating. From Eq. (6), we can observe
that the T2 relaxation rate (R2) is dependent on the ms value. Given
that the magnetic properties of the SPMNPs are dependent on physi-
cochemical parameters, such as size and composition and can be easily
tuned by controlling these, it is possible to develop SPMNPs with large
ms values to achieve high T2 contrast effects. In contrast to T2, T1 con-
trast effects are the result of magnetically disordered spin layers at the
surfaces of the MNPs. The metal ions at the NPs surface have a num-
ber of unpaired electrons; for example, Fe3þ have 5 unpaired electrons
that in entirely accelerate the T1 relaxation process. However, high
magnetization of MNPs with high r2 and r2/r1 values is inadequate for
T1 contrast agents. Broad r1 while decreasing r2 and r2/r1 values is the
ultimate solution for improving T1 contrast effect; this can be possible
with increasing the share of canted surface spins of MNPs by decreas-
ing the size of the MNPs. Theoretical investigation suggested that the
optimum size of MNPs should be smaller than 10 nm to achieve
strong T1 contrast effects.
102
b. Magnetic particle imaging. The use of MRI and contrast agents
in cancer theranostics has a long history. MRI provides quality imag-
ing of tumor and information for theranostics, but for more accurate
tumor diagnosis, a higher resolution, real-time in vivo imaging and
monitoring is required. In particular, tomographic imaging has
become a radical tool for visualizing tumor lesions, showing selectivity
of diseased and normal tissues and monitoring blood ﬂow in the
human body. The magnetic particle imaging (MPI) technique discov-
ered by Gleich and Weizenecker at Philips Research Laboratories in
Hamburg evolved into a tomographic imaging method for high spatial
and temporal resolutions of tumors.105 MPI is driven by the physics of
its tracers, which are typically MNPs or SPIONs. The MPI signals rely
on the nonlinear remagnetization response of SPIONs to an oscillating
MF. If MNPs (typically SPIONs) are exposed to an oscillating MF
with frequency (f1) and amplitude (A), the MNPs will exhibit a magne-
tizationM(t), where (t) is the time. The relationship between the AMF
and the resulting magnetization M(t) is nonlinear. At this stage, the
MNPs can either undergo a Brownian rotation (physical particle rota-
tion) or Neel rotation (internal magnetic moment rotation). These
relaxation properties of SPIONs in the presence of an AMF afford the
foundation for signal generation and acquisition in MPI.106 Since the
relationship between the AMF and the resulting magnetization of
SPIONs is nonlinear, this leads to harmonics in the detected signal
(Fig. 7). These produced harmonics can then be used to quantify the
local concentration of the SPIONs by a simple Fourier transform as
illustrated in the equation below106
Sn ¼ Fourier u tð Þ
 
; u tð Þ / cdM tð Þ=dt; (7)
where Sn is the SPIONs harmonics, u is the voltage signal measured in
the receive coils, c is the concentration of the SPIONs, and M is the
magnetization of the SPIONs. The generated higher order harmonics
for a nonlinear magnetization curve can be further mathematically
expressed by expanding the Langevin function into a Taylor series.106
FIG. 7. Schematic representation of the MPI image generation workﬂow, comparing harmonic-space and x-space MPI. The MPI image generation process can be divided into
four steps: (a) tracer selection and characterization, (b) excitation and spatial localization and signal reception. Reproduced with permission from Bauer et al., J. Phys. Chem.
Lett. 6, 2509 (2015). Copyright 2015 American Chemical Society.103 (c) Hardware setup of the MPI scanner designed at Department of Bioengineering, University of California
at Berkeley. Reproduced with permission from Tay et al., ACS Nano 12, 3699 (2018). Copyright 2018 American Chemical Society.104
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After the raw data or signals captured for MPI, reconstruction algo-
rithms are used to facilitate the conversion of signals into images. Two
principal methods of image reconstruction techniques have been
reported to date: harmonic-space MPI and x-space MPI. The physics
of these techniques is underlined in recent review articles and book
chapters.103,107,108
2. Clinical progress
Advancements in nanotechnology over the last three decades have
led to the development of novel magnetic imaging modalities for cancer
theranostics. Owing to the need for precise imaging of tumor boundaries
in complex environments, new MNPs based multimodal imaging tech-
niques are in progress. The HNCs (including various type of bare and
functionalized MNPs) studied over the last decade allow multimodality
to overcome the inherent instrumental limitations of magnetic imaging
systems for tumor imaging. In particular, MNPs are used to improve
sensitivity, resolution, and accuracy of the magnetic imaging modalities.
Over the years, various synthetic, structural, physicochemical, and mag-
netic imaging aspects of nanomaterials have been discussed in a number
of excellent reviews.98,102,109,110 Here, we summarize the updated state-
of-the-art clinical research on HNCs developed for magnetic imaging in
cancer theranostics (including therapy monitoring by MRI and MPI).
While previously discussed issues like MRI contrast enhancement, NPs
physical and chemical parameters, preliminary in vitro and in vivo stud-
ies, etc., will not be covered in the present section.
The next generation multimodal-imaging nanoprobes offer a novel
approach, which can provide detailed diagnostic information for the
planning of image-guided diagnostics and therapy including surgery
monitoring, via the application of biocompatible nanomaterials integrat-
ing MRI in clinical practice. In recent time, catheter-directed hybrid
magnetic microspheres based drug delivery and MRI-guided cancer
nanotheranostics approaches have been proposed to treat cancer effe-
ciently.111 This approach offers cancer patient-speciﬁc personalized
medicine, which permit dosimetry and tumor-speciﬁc treatment of liver
tumor with reduced systemic toxicity and superior therapeutic effect.
Researchers from the Center for Nanomedicine, Institute for Basic
Science (IBS) Seoul, Republic of Korea, introduced distance-dependent
magnetic resonance tuning (MRET) for the noninvasive exploration of
a wide range of biological events in deep organs including tumor.113 To
demonstrate this nanotheranostics potential, a three component system
was developed, enclosing paramagnetic enhancer Gd-1,4,7,10-tetraaza-
cyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) core with superpara-
magnetic quencher (12nm Zn0.4Fe2.6O4 NPs) and a thick layer SiO2
(18nm). The enhancement of T1 MRI signal is obtained at the tumor
region, which is providing high-resolution anatomical information and
soft tissue contrast without a penetration depth limit which is difﬁcult to
achieve with current optics-based approaches.
Existing MRI modalities coupled with contrast agents rely on
single-phase contrast enhancement of tumor, which is not sensitive
enough to detect and monitor early stage small hepatocellular carcino-
mas (HCCs), especially those less than 1 cm in size. Diagnosis accom-
panied by timely curative monitored treatments of these small early
stage HCCs can increase the median 5-year survival rate of patients
from 5% to over 50%.112 Two different versatile MRI based nanoplat-
forms are proposed by different research groups (Fig. 8). The ﬁrst
approach was based on an intelligent MRI contrast agent, termed
responsive iron oxide nanocluster assembly (RIA). This was fabricated
by linking iron oxide with i-motif DNA-derived pH-responsive link-
ers.112 The HNCs shorten the transverse relaxation time and the initia-
tion of MRI modular switch from T2 to T1. A second nanoplatform
deals with developing lanthanide-based upconversion MNPs
(UCNPs) to serve as multimodal-imaging reporter providing tumor-
speciﬁc detection, surgical intervention, and image-guided surgery for
resection of HCCs.114 Compared with T2 or T1 (“turn-on”) contrast
enhancement designing T2–T1 switching contrast agents is usually
more desirable for accurate tumor diagnosis at clinical stage. These
next generation contrast agents enable “brightening” imaging with
high sensitivity and signal-to-noise ratios. Yang and his research group
from Shanghai Normal University have reported Fe3O4-based T2–T1
switching MRI contrast agent for distinguishing between normal tissue
and tumor tissue in vivo, by utilizing pH- and GSH-responsive ZIF-
8 (Zeolitic imidazole frameworks) as a matrix.115 In preclinical stage
novel HNCs show T2–T1 weighted switching in mice liver sites and
enhanced contrast darkening. The tumor sites exhibited darkening to
brightening contrast enhancement, giving larger inverse contrast for
differentiating the normal tissue and tumor tissue boundaries. Over
the past few years, various novel HNCs have been proposed in cancer
nanotheranostics to guide therapy using MR and computed tomogra-
phy (CT) imaging. This include magnetoplasmonic NPs in Brain can-
cer,116 silica coated metal chelating-melanin NPs in protest cancer,117
and hybrid iron oxide nanocubes for natural immunotherapy of liver
tumor.118
In clinical instances, numerous cancerous tumors are not easily
accessible or amenable to surgery and radiotherapy but can be reachable
to magnetic ﬁeld and thus MFH combined with MPI could perhaps be
more effective and appropriate. The next generation cancer nanothera-
nostics often involves cancer-targeting SPIONs administered intrave-
nously for MPI followed by MFH. The MPI can monitor blood ﬂow to
the tumor via SPION tracers and could assess the efﬁcacy of the treat-
ment, as well as monitoring metastasis through sentinel lymph nodes.
MFH can further reduce the burden of aggressive tumor progression by
suppressing cancer cell resistance to chemotherapeutic drugs. A proof of
concept was demonstrated in a preclinical setting by Hensley et al., in
the year 2017.119 Simulation and experimental work were carried out to
quantify the extent of spatial localization of MFH using MPI systems.
Combined MPI-MFH system performed on-demand selective heating
of MNPs samples separated by only 3mm (up to 0.4 C s1 heating
rates and 150W g1 SAR deposition) allowing for spatially selective
heating deep in the body and generally providing greater control and
ﬂexibility in MFH. This novel nanotheranostics approach was further
clinically validated by Tay and coworkers.104 The research group dem-
onstrated a nanotheranostics platform, with quantitative MPI image
guidance for treatment planning and use of the MPI gradients for spatial
localization of MFH to arbitrary selected regions of the liver tumor while
minimizing collateral damage to the nearby liver (1–2 cm distance).
Apart from localizing cancer therapy, the system can be extended to
localize actuation of drug release with high contrast and high sensitivity
imaging combined with precise control and localization of the actuated
therapy. Clinical experimental data validated that the MPI-MFH thera-
nostics platform can selectively heat tumors separated by 7mm with
negligible heating of off-target sites, by delivering SPOINs to the target
site (Fig. 9). There is growing interest to further develop the ﬁeld of can-
cer nanotheranostics combined with MPI.120 Biomedical engineers are
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designing MPI clinical machine/techniques for improved acquisition
and reconstruction.121 At present, we are at the very beginning of
exploring MPI-MPH in cancer therapy, with optimal instrumentation,
SPIONs, and image formation in place, it will be the time for oncolo-
gists, biomedical engineers to take MPI-MFH to the next generation for
discoveries in cancer nanotheranostics.
D. Future opportunities and challenges
These are indeed very exciting times for the development of mag-
netically stimulated cancer nanotheranostic systems with different
MNPs/SPIONs/SPMNPs as carriers. The current step of technological
advancement gives the impression of further progress in the clinical
development and that should be a goal in the near future. Although
clinical translation of magnetically stimulated cancer nanotheranostics
is still in its ﬁrst phase, scientist working on the development of this
emerging technology anticipate it will compete strongly with other
modalities now routinely used in disease diagnosis. The most exciting
aspect of magnetically induced theranostics with various types of
MNPs is their potential to be equipped with many spatial therapeutic
effectors, with a selective external control. However, even at this
median stage, when ﬁrst-hand novel concepts and strategies for MF
based external release systems are only beginning to be realized in
FIG. 8. MRI guided cancer nanotheranostics approaches. Approach 1: designing HNCs with DNA-modiﬁed ultrasmall iron oxide nanoclusters (USIONCs) cross linked by pH-responsive
linker DNAs to fabricate the responsive iron oxide nanocluster assembly (RIA). Upon intravenous injection, RIAs are routinely sequestrated by Kupffer cells in liver, whereas they disassem-
ble into dispersed USIONCs when extravasated in the acidic HCC tumor environment. Under T1-weighted MR imaging (T1WI), the normal liver appears dark due to the presence of RIAs,
while the HCC tumor becomes bright by the USIONCs. Schematic of multimodal MR/upconversion luminescent imaging of HCC tumor using transcatheter hepatic intra-arterial. Panel 2:
clinical small HCC diagnosis by RIAs. (A) T1 weighted images RIAs (responsive iron oxide nanocluster assembly) and (B) IRIAs (pH-irresponsive iron oxide nanocluster assemblies) in
orthotopic HCC mice. Reproduced with permission from Lu et al., J. Am. Chem. Soc. 140, 10071 (2018). Copyright 2018 American Chemical Society.112 Approach 2: Schematic of multi-
modal MR/upconversion luminescent imaging of HCC tumor using transcatheter hepatic intra-arterial (IA) targeted anti-CD44-Nd-CSUCNPs. Next generation multimodal diagnostic MR
and intraoperative upconversion luminescence (UCL) image-guided surgery for HCC resection were demonstrated. Panel 2: (a) MR T2 weighted images of rats after IA delivery conﬁrming
HCC detection of anti-CD44-Nd-CSUCNP imaging reporters, (b) digital imaging of HCC lesion, (c) detection of HCC with UCL imaging of IA targeted anti-CD44-Nd-CSUCNPs and NIR
light (808 nm), (d) an image of liver after image-guided hepatic electrocauterization resection, (inset) UCL imaging of resected HCC tissue with NIR light (808 nm). Reproduced with permis-
sion from Lee et al., Biomaterials 109, 69 (2016). Copyright 2016 Elsevier Ltd.114
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preclinical tests, it is important to focus on the potential and relevance
of these technologies in the clinical oncology. Magnetically triggered
nanotheranostics modality is advantageous to address important
shortcomings of current cancer therapies based on nanotechnologies,
for example; (i) direction of NPs carriers to tumor tissues with precise
external control deep within the human body, (ii) triggered release of
chemotherapeutic cargo at this depth with precise remote control, (iii)
MFH promotes bursting elimination of the tumor tissues without off-
target effects and without the possibility or tumor reoccurrence, (iv)
image guided cancer therapy preprocedure planning and identifying
tumor volume, (v) magnetically guided catheters promoting intrapro-
cedural tumor targeting, (vi) MPI is advancing state of the art of tumor
monitoring before and after the treatment, (vii) intraprocedural and
postprocedure treatment control assessment such as measuring effec-
tiveness for further intervention. The real present-day challenge in the
design of such a novel technology is related to concerted effort from
specialists in each ﬁeld such as physics, spectroscopy, chemistry, biol-
ogy, medicine, and oncology. The other limitation is linked to HNCs
development toward maintaining biocompatibility, as well as combin-
ing multiple magnetically induced release mechanisms. A major chal-
lenge for novel HNC design is to prevent mineral leaching from the
inorganic core and organic shell and continues to permit clearance
from the body in an appropriate time frame. Furthermore, achieving a
100% therapeutic effect without damaging surrounding healthy tissues
is the challenge of MFH therapy. Finally, addressing each of these
shortcomings requires a concerted effort from nanotechnologists and
clinicians.
IV. LIGHT-STIMULATED NANOTHERANOSTICS
The use of light in modern medicine medical practices began in
the late nineteenth century. The physician Niels Finsen was awarded
the Nobel Prize in Physiology and Medicine in 1903 for phototherapy
based on ultraviolet (UV)-induced treatment of lupus vulgaris. This
fundamental light–matter interaction discovery leads to swift improve-
ments in the understanding of light in medicine to diagnose and cures
various diseases. The light or photons interact with biological tissue
and biological matter via various processes, for example, scattering
and absorption of light within tissues. This is summarized in Fig.
10(a). Since the discovery of the laser in 1960, new medical avenues
have been opened for biomedical engineers and clinicians. Today,
lasers are routinely used in medical applications, including eye surger-
ies, cutaneous disorders, and tumor tissue ablation through ﬁber-optic
delivery. Recent advances in optical technologies and biomedical engi-
neering have enabled biomedical devices, in particular, those that
FIG. 9. MPI guided MFH cancer therapy in clinical stage. (a) Setup of the MPI scanner and the image-guided magnetic hyperthermia scanner. (b) Illustration of MPI-localized
heating in the tumor while sparing the liver. Experimental demonstration that MPI can predict the spatial distribution of heating for image-guided, gradient-localized magnetic
hyperthermia. Reproduced with permission from Tay et al., ACS Nano 12, 3699 (2018). Copyright 2018 American Chemical Society.104
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coupled nanotechnology with photonics and laser. This has led to a
global market for therapeutic lasers estimated to be over US$3
billion.122
Nanotheranostic integrated into one entity is executing
multiple functions and multimodalities with different functions.
Multiple light-triggered functions could be easily integrated into
one single nanoplatform. Nanotheranostics multifunctionality in a
well-deﬁned pattern through elegant but feasible construction is
challenging for a conventional molecular design and synthesis per-
spective.123 Light-induced cancer nanotheranostics are normally
responsive to ultraviolet (UV), visible (Vis), and near infrared
(NIR) light, although this is heavily dependent on the properties of
nanomaterials. For instance, commonly reported organic and inor-
ganic photosensitizers (PSs), zinc phthalocyanine (ZnPc), indocya-
nine green (ICG), zinc oxide (ZnO), titanium oxide (TiO2), and
quantum dots (QDs) are responsive to UV, Vis, or NIR light and
are used in photodynamic therapy (PDT). Moreover, polyaniline
(PANI), polypyrrole (PPy), gold (Au) nanorods, Cu2-xS NPs,
nanoreduced graphene oxide (RGO), and single-walled carbon
nanotubes (SWNTs) are triggered by NIR light and are used as
photothermal therapy (PTT) agents. Furthermore, in order to
enhance the therapeutic efﬁciency of light-triggered therapies and
at the same time avoid the contrary side effects of the monotherapy
(PTT or PDT), the combinational use of different light-triggered
therapies in a single platform was developed. Due to the rapid
development of the ﬁeld of materials science, thanks to nanotech-
nology, different light-triggered cotherapy modalities have been
well developed by designing smart multifunctional materials such
as HNCs, into which several different types of therapeutic agents
together with imaging agents can be combined.124
FIG. 10. Light–tissue interactions. (a) Representative optical mechanisms used in diagnosis and imaging (left), and surgery and therapy (right). Circular objects denote incom-
ing and outgoing photons, with their trajectories indicated by solid and dotted arrows. Colors of the circles represent the spectrum of the light; dotted circles indicate the absorp-
tion of input photons. For the case of therapy, speciﬁc effects of light on tissue and cells are indicated. Reproduced with permission from S. H. Yun and S. J. J. Kwok, Nat.
Biomed. Eng. 1, 0008 (2017). Copyright 2017 Macmillan Publishers Limited, part of Springer Nature.122 (b) Schematic representation of the parameters related to the laser light
that inﬂuence the PTT mediated by nanomaterials. In the wavelength panel, the bars represent the absorption of different biocomponents, and the color intensity is proportional
to their absorption at that speciﬁc wavelength. Reproduced with permission from de Melo-Diogo et al., Adv. Healthcare Mater. 6, 1700073 (2017). Copyright 2017 WILEY-VCH
Verlag GmbH & Co. KGaA, Weinheim.125 (c) Energy diagram for a conventional organic photosensitizer, molecular oxygen, and related photophysical and photochemical pro-
cesses. Abbreviation: hv, one-photon absorption; 2hv, two-photon absorption; S0, ground state; S1, singlet state; T1, triplet state. Fluorescence, photothermal therapy, and pho-
todynamic therapy are related to different transformation processes of the absorbed energy. Reproduced with permission from Chin et al., Biomater. Sci. 5, 1491 (2017).
Copyright 2017 The Royal Society of Chemistry.126
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A. Photodynamic therapy
1. Underlying physics
Photodynamic therapy (PDT) is a physicochemical dynamic pro-
cess that involves three principal components: a photosensitizer, light,
and oxygen. All these components interact with each other on the
same time scales relevant to a single treatment. Fundamentally, the
photodynamic process depends on the photosensitizer molecule, as
well as the nanomaterial itself. A photosensitizer (PS) absorbs a pho-
ton of light and becomes activated from ground state (S0) to a short-
lived excited singlet state (S1) [Fig. 10(c)]. This excited state and the
ground state are spectroscopic singlet states. The excited PS may either
decay back to the ground state by generating ﬂuorescence or it can
endure an intersection journey through which the spin of its excited
electron reverses to form a relatively prolonged triplet state.127 On the
other hand, a high probability of transition from S1 to an excited triplet
state T1 is possible. The triplet excited PS can then directly transfer its
energy in the form of proton or an electron to a substrate, such as the
cell membrane or a molecule. This energy transfer process forms a
radical anion or cation, which then reacts with oxygen to produce oxy-
genated products such as superoxide anion radicals (O2), hydroxyl
radicals (.OH), or hydrogen peroxides (H2O2) (type I reaction).
Alternatively, in the T1 state, the photosensitizer can transfer energy to
molecular oxygen (3O2) exciting it to its highly reactive singlet state
(1O2)
128 (type II reaction). Very small amount of energy (22 kcal
mol1 corresponds to wavelength of 1274nm) is required to produce
1O2 through the transition of oxygen from triplet ground state to
excited singlet state.127 The resulting derivatives of this process are
type I and type II reactions that are responsible for the therapeutic
PDT effect.
In cancer theranostics, PDT depends on the ability of PS to trans-
fer energy from lasers to tumor-dissolved oxygen (O2) to generate
cytotoxic singlet oxygen (1O2), and its effectiveness is impaired by an
inadequate oxygen supply in tumors.129 Thus, a cumulative dose of
singlet oxygen is an essential factor, which is presumed to be predictive
of tissue damage. This prediction is quantitatively assessed predicted
by using dosimetry techniques. The prediction of singlet oxygen dose
on the basis of measurable quantities that contribute to the photody-
namic effect such as the distributions of light, photosensitizer, and
oxygen is subject to dosimetry. Strategies, physical principles, and
measurement techniques of explicit, direct, and implicit dosimetries
are summarized in a recent review article.128 The other parameter
inﬂuencing PDT is the wavelength of light used within “therapeutic
window.” This is typically between 600 and 800nm. In this wavelength
range, the energy of each photon (ht) is moderate (1.5 eV) to excite
the PS but low enough to penetrate into the deep tissue and tumor.
The invention of laser allowed the production of monochromatic light
that could be easily coupled into optical ﬁbers. Together with optical
ﬁber light source and theranostics NPs, next generation cancer nano-
theranostics enabled PDT at desired regions (tumor) without the
requirement of a straight light path and complex nanostructures that
are responsive to visible light or NIR light for indirect PDT activation.
Finally, the underlying physical phenomenon governing PDT in can-
cer theranostics is the absorption and emission of a photon with a
“Stokes shift” in wavelength and transferring the energy into heat
interacting by surrounding environment, or conversion from singlet to
triplet state, resulting into the generation of reactive oxygen species
(ROS), accompanied by photon emission type I or type II (1O2)
reactions.
2. Clinical progress
PDT is an emerging tumor therapy that relies on light as a spa-
tially and temporally precise stimulus. Optical illumination of light
sensitive drug encapsulated NPs or PS selectively destroying malignant
cells without the side effects associated with systemic treatments such
as chemotherapy.130 At the clinical stage, the success of PDT depends
on the potential of PS to transfer energy from lasers to tumor-
dissolved oxygen (O2) to generate cytotoxic singlet oxygen (
1O2).
However, this success of PDT is impaired by an inadequate oxygen
supply in tumors. Established nanotheranostic methods have
attempted to optimize tumor oxygenation (hypoxia) to ensure PDT
efﬁcacy. These approaches only affect PDT-induced oxygen depletion,
whereas the pre-existing hypoxia cannot be reversed, which is a big
barrier to its clinical use. Therefore, developing new technique, which
can reverse the tumor oxygen content during PDT, has the great
importance for clinical success. Pre-existing hypoxia in tumors and
oxygen consumption during PDT can result in an insufﬁcient oxygen
supply, which, in turn, hampers photodynamic efﬁcacy. The problem
associated with conventional PDT has been resolved using oxygen
self-enriching PDT (Oxy-PDT) by loading a photosensitizer into per-
ﬂuorocarbon nanodroplets.129 In clinical studies, a single-dose intrave-
nous injection of Oxy-PDT into tumor-bearing mice signiﬁcantly
inhibits tumor growth, whereas traditional PDT has no appreciable
effect. On the other hand, decorating platinum on photosensitizer
integrated metal organic frameworks (MOFs) can also enhance PDT
and resolve the pre-existing hypoxia in tumors.131 Inadequate blood
ﬂow and oxygen supply in the central region of solid tumors cause
hypoxia. The conventional oxygen-dependent PDT and chemotherapy
are considerably limited to utilize extra oxygen delivery into tumors.
Another example of using next generation nanotheranostics to deliver
oxygen into a tumor use lanthanide ion-doped mesoporous hollow
upconversion NPs loaded with a chemotherapeutic drug such as doxo-
rubicin. This can achieve endogenous intratumoral H2O2-responsive
self-sufﬁciency of O2 and NIR light controlled PDT simultaneously for
overcoming hypoxia cancer.132
In addition to those technologies that focus on replenishing hyp-
oxia in tumors, new paradigms can generate singlet oxygen (1O2)
under NIR photoirradiation along with chemotherapeutic action in
hypoxic tumor microenvironment to diminish O2 dependence. The
clinical proof of concept has been validated by developing a semicon-
ducting polymer nanoprodrug (SPNpd).133 The well-deﬁned and
compact hybrid SPNpd (30nm) are assembled from amphiphilic
polymer brush, which comprises a light-responsive photodynamic
backbone grafted with poly(ethylene glycol) and conjugated with a
chemodrug through hypoxia-cleavable linkers. This newer approach
has advanced the production of singlet oxygen in the tumor to tackle
the cancer. Cancer cells in hypoxic tumors are often remarkably resis-
tant to PDT, and thus next generation PDT nanotheranostics line of
action is required. This has been addressed recently, by the develop-
ment of a nanocomposite that contains Pt(IV) and chlorin e6, in
which upconversion NPs are loaded to convert 980 nm near infrared
light into 365nm and 660 nm emissions.134 In clinical experiments,
this nanocomposite accumulated at the tumor site. A 980nm laser was
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used to trigger the nanocomposite to generate O2 for consumption in
the PDT process and releases active Pt(II) for synergistic photo-
chemotherapy to enhance PDT antitumor efﬁciency. Earlier work
published in 2018135 reports type II PDT to overcome the tumor hyp-
oxia barrier. Type II PDT is a form of phototherapy involving light
and a photosensitizer. Researchers successfully fabricated O2-generating
HSA-MnO2-Ce6 NPs for enhanced photodynamic effect by conjugating
molecular oxygen (O2) to produce singlet oxygen (
1O2). This approach
leads to cellular necrosis and apoptosis in bladder cancer by overcoming
hypoxia. As a minimal or noninvasive nanotheranostics approach for
tumors, PDT induced by external laser irradiation coupled with various
nanosystems has appealed excessive devotions to treat various types of
cancers at the clinical stage, including nanoliposomes,136 magnetoﬂuor-
escent carbon dots137 and biomimetic MnO2@PtCo nanoﬂowers
138
(hypoxia breast tumor), phosphorus nanosheet139 (HeLa tumor), cal-
cium carbonate-polydopamine nanocomposite140 (skin tumor), 5-
ﬂuorouracil (5-FU)-loaded silk ﬁbroin NPs141 (gastric tumor), supramo-
lecular silicon-containing nano dots nanogel142 (lung cancer), chemilu-
minescence resonance energy transfer (CRET)-based biomimetic silica
nanoreactor143 (lung metastasis tumor), and many others which are
reviewed in recent review articles.144,145
3. Next generation PDT device design
The low penetration depth to less than a centimeter of light
within tissues currently limits the therapeutic efﬁciency of PDT
even at NIR wavelengths. Presently, optical ﬁbers inserted through
surgery or endoscopy are used to deliver light into deeper tissue
regions. However, this approach allows only a single light dose to
be delivered and is incompatible for long-term implantation. To
deal with this issue, scientists from the National University of
Singapore developed a nanotheranostic approach based on a wire-
less photonic device that enables on-demand light activation of
photosensitizers deep in the body for targeted PDT. The biomedical
engineering approach used to treat tumors allows deep operation
near organs at human size scales, multiwavelength light emission at
radiant power levels for nano photosensitizer activation, and wire-
less control of light emission for therapeutic dosimetry (Fig. 11).
The wireless delivery of light deep in the body in situ by activating
photosensitizers can potentially provide advantages in the clinical
stage to treat hepatocellular carcinomas or brain tumors. On the
contrary, Yuji Morimoto and colleagues made up a wireless PDT
system for metronomic cancer treatment (low-dose and long-term
PDT)130 that uses stretchable poly(dimethylsiloxane) (PDMS)
nanosheets modiﬁed with mussel-footprotein-derived bioadhesive
polydopamine (PDA).146 Ultrathin PDMS nanosheets fabricated by
a roll-to-roll process, and decorated with PDA, can form strong
chemical bonds with biological tissue surfaces.147 The designed
nanodevice is showing strong antitumor effects and could be an
alternative to current therapies used to treat localized tumors,
favoring the clinical applicability of the PDT in fragile or delicate
organs system. Researchers in the Fudan university fabricated a
NIR rechargeable “optical battery” for irradiation-free PDT. The
nanodevice embeds upconversion materials, and a persistent lumi-
nescence materials, photosensitizer into biocompatible polydime-
thylsiloxane.148 The optical battery can be continuously charged
using 980-nm NIR laser within very short time (5 s) to generate
singlet oxygen in deep tissue (4mm) under green persistent lumi-
nescence with low photothermal effect. The effective deep tumor
proliferation inhibiting capability of this NIR rechargeable optical
battery may give rise to the next generation of intelligent stimuli-
responsive nanotheranostics in the clinic. Endo-laparoscopy based
on endoscopic equipment is a technique used in the treatment of
gastrointestinal cancer, which could also be used to deliver light to
tumor sites. The combination of endoscopic light guidance with
NPs based photosensitizers makes it possible to treat cancer via
PDT, which would be difﬁcult to treat with endo-laparoscopy
surgery or PDT. Kim et al. designed a polymeric nanoassembly
conjugating tumor targeting aptamers to perform effective endo-
laparoscopic PDT.149 Under laser light irradiation, the nanoassem-
bly not only showed improved tissue penetration but also induced
the death of tumor cells through apoptosis, signifying great poten-
tial to be translated into clinics for endoscopic tumor diagnosis and
treatment.
B. Photothermal therapy
1. Underlying physics
Photothermal therapy (PTT) relies on the photothermal effect of
photothermal transduction agents (PTAs) that can harvest the energy
from light and convert the energy into heat. The heat generated
(42.5–43.0 C) can be further utilized to trigger the death of tumor
cells by photohyperthermia. Metallic NPs are efﬁcient PTAs that con-
vert electromagnetic radiation into heat via plasmonic resonances.150
This feature has been displayed by several types of metallic nanostruc-
tures produced with gold, carbon, copper, molybdenum, tungsten,
iron, palladium, or novel new generation HNCs. Different strategies to
improve NPs mediated cancer PTT have been highlighted in a recent
review article.125 NPs optical response is a function of scattering (rScat)
and absorption cross sections (rAbs). The heating power (P) of a
metallic NPs under continuous light exposure is proportional to the
incident light intensity and the absorption cross section of NPs: P¼ I
 rAbs. The absorption cross section of metal NPs is inﬂuenced by the
size, shape, and elements of NPs. When nanostructures are irradiated
with light, the excited electrons rapidly accumulate on their surface,
which is known as localized surface plasma resonance (LSPR) effect.
Electronic oscillation in the nanostructures will dampen via transfer-
ring energy to the environment in the form of heat. The penetration of
light into deep tissues is limited due to the attenuation of human tis-
sue. This could be resolved by utilizing light sources at certain wave-
lengths where the human body is most transparent {biological
transparency windows [Fig. 10(b)]}. So far, PTAs are built to respond
to the NIR-I (700–950nm) and NIR-II (1000–1350nm) regions in
clinically demonstrated PTT. Very recently, advancing optics and bio-
medical engineering developed novel photodetectors technology that
gave new transparency windows at longer wavelengths: NIR-III
(1600–1870nm) and NIR-IV (2100–2300nm) for PTT.150 Utilizing
NIR-III and IV assures better light penetration into deep tissue with
less attenuation. Alternatives to overcome the light penetration issue
are to use ﬁber optics to transmit light through human body into
tumors and activate PTAs for effective PTT outcome. Acting as a
stand-alone conventional laser based PTT, NPs mediated PTT pro-
vides efﬁcient light-to-heat conversion and the ability to penetrate tis-
sue more deeply than of light by tuned absorption of NIR light.
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FIG. 11. Next generation wireless pho-
tonic PDT device. (a) Schematic of the
PDT therapy. The therapy consists of
implantation of a wireless light emitting
diode (LED) near the target region, admin-
istration of the photosensitizer, and wire-
less powering of the device. Light emitted
by the device locally activates the photo-
sensitizers and induces tumor damage.
(b) Image of the wireless photonic device
emitting light. (Inset) The device illuminat-
ing an explanted tumor. (Scale bar, 2 mm.)
(c) Schematic of the device and individual
electronic components. (d) Optical emis-
sion spectrum of the device from two
LEDs. The emission wavelengths are cen-
tered at 400 nm (violet) and 660 nm (red),
overlapping with the absorption peaks in
the Ce6 spectrum. (e) Illustration of light-
delivery conﬁguration for irradiating MB49
cells using laser and device, with and
without intervening thick porcine tissue.
Near-ﬁeld (NF) wireless powering is used
at close proximity and midﬁeld (MF) for
thick tissue. (f) In vivo PDT, CT recon-
structions of representative mice in each
group 13 days after ﬁrst treatment. White
arrows show implant position. (Scale bar,
1 cm.). Reproduced with permission
Bansal et al., Proc. Natl. Acad. Sci. U. S.
A. 115, 1469 (2018). Copyright 2018
license under a Creative Commons
Attribution 4.0 (CC BY-NC-ND 4.0)
International License, PNAS License.130
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2. Classification of nano PTAs
The past few decades have witnessed rapid developments in
nanotechnology toward developing novel NPs and “smart” PTAs for
PTT. Ideally, PTAs transform energy from absorbed light into heat
and increase the temperature of the solid tumor. PTAs are usually cat-
egorized into inorganic and organic materials. Inorganic PTAs contain
noble metals, graphene and carbon nanotubes (CNT), and boron
nitride NPs. Organic PTAs include NIR-responsive small molecules
and semiconducting polymer NPs.151 Among the inorganic NPs, gold-
based nanostructures like gold NPs (AuNPs), nanorods (GNRs) nano-
cages, nanohexapods, nanoshells, and nanostars have been intensely
investigated for PTT. An important feature of Au NPs is that their size
range can be easily varied to yield maximal absorption within the ﬁrst
NIR window (650–850nm), which can safely penetrate 2–3 cm of tis-
sue. Different from AuNPs, GNRs have a short and long axis, thereby
showing two absorption peaks corresponding to the transverse (k
 500–550nm) and longitudinal (k  650–850nm) surface plasmon
resonance (SPR).152 The latter strongly depends on the nanorod shape
and can be adjusted to the NIR region by increasing the ratio aspect of
nanorods. Using the novel synthesis ways, GNRs dimensions can be
shortened or elongated to achieve peak longitudinal SPR in the NIR
region. GNRs with dimension 10nm 40 nm, for example, can maxi-
mally absorb 800nm light and are therefore the most common for
PTT. At present, many other inorganic carbon based nanostructures
such as carbon nanotubes (CNT) and nanographene oxide (nGO) are
being actively studied for tumor PTT. The other inorganic nanostruc-
tures studied for PTT at the preclinical stage are copper (Cu) based
copper sulﬁdes (e.g., Cu2–xS nanodots, Cu7.2S4 nanocrystals), molybde-
num (Mo), tungsten (W), iron (Fe), palladium (Pd) based NPs, Mo
and W-based oxides (e.g., MoO3–x hollow nanospheres, WO3 nano-
particles) and disulﬁdes (MoS2 and WS2 nanosheets), and Pd nano-
sheets, etc.125 On the other hand, only a few organic nanostructures
such as polyaniline (PANI), polypyrrole (PPy), and poly(3,4-ethylene-
dioxythiophene) (PEDOT) plasmonic nanoliposomes are found to be
effective in PTT.153 Even though encouraging PTT of tumors in small
animals has been reported over the decade using these NPs mentioned
above, clinical translation has been extremely slow, as very few of these
NPs are now under clinical trials.154 Many comprehensive reviews,
addressing synthesis processes, physical chemical properties of NPs,
and their relevance to PTT, have already been published.125,151,152,155
Among this, plasmonic GNRs have reached the clinical stage because
of their strong photon energy absorption cross section and ability to
transduce light into heat with high efﬁciency. However, the state of the
art of clinical research stage and new generation nanotheranostics
PTT devices are not being reviewed yet. Thus, we are focusing on the
most up-to-date PTT devices advancing the nanotheranostic and clini-
cal stage reports, in Sec. IVB3.
3. Clinical progress
PTT combined with nanotechnology has become a powerful tool
to treat cancer. Despite the tremendous development in PTT coupled
with different NPs, there are still major obstacles to clinical translation
such as design and engineering, batch-to-batch variation, lack of veriﬁ-
cation of therapeutic efﬁcacy in tumor site, difﬁculty of site-selective
thermal dosing, and relatively limited size of ablation zones. To
address these core issues, an HNCs based smart nanotheranostic
approach has been proposed by Liu and coworkers.156 This smart
nanoplatform consists of a core of magnetic gold nanowreaths, which
provides excellent photothermal property, and a shell is made from
the self-assembly of exceedingly small IONPs. The novel HNCs not
only enhanced their tumor accumulation by inhibiting their fast-renal
clearance but also generated glutathione (GSH)-responsive MRI T1
signal in the tumor microenvironment. In addition to the bright T1
imaging, HNCs were also able to greatly enhance the photoacoustic
imaging contrast in the tumor, which further helped to determine the
site-selective PTT dosing and best time point to conduct PTT. In
another recent study, unique rabies virus-mimetic silica coated GNRs
were used to overcome the blood brain barrier (BBB) and treat brain
tumor using PTT.157 Importantly, it is of great interest that these
nanorods not only resembled the appearance of the live rabies virus
but targeted the brain through the neuronal pathway bypassing the
BBB. Also, smart HNCs were able to induce photothermal effect in
response to NIR laser (808 nm) irradiation, based on localized SPR, to
effectively suppress brain tumors during clinical experiments using
nanotheranostics platform.
The scattering and absorption of light in biological tissue strongly
imped the penetration of laser light. Thus, it is difﬁcult to determine
the distribution of light into an organ to evaluate the temperature dis-
tribution at different depths of a tumor tissues. In a conventional PTT
approach, tumor cells were injected subcutaneously, NPs were admin-
istered systemically or locally, and laser light was typically applied to
the skin at an intensity of higher than the threshold limit (420 mW/
cm2) for the induction of PTT. This approach induces skin damage
due to thermal injury, and hence, a new nanotheranostic practice that
utilizes NIR laser light and NPs without inducing skin damage is
required. Sugiura and his group from the Tohoku University, Japan,
have designed a new NPs based PTT protocol involving computational
simulations for the treatment of aggressive metastatic tumor using
NIR laser light, GNRs, and a skin temperature control system.158 The
temperature distribution and region of the tumor showing damage
were determined by numerical analysis after considering the degree
of light scattering. Using this new light based cancer nanotheranostic
concept, researchers were able to eliminate cancer tumor under NIR
irradiation and advance effective anticancer therapy that did not
induce macroscopic skin damage. The adequacy of cancer PTT
involves a balance between eradicating the entire lesion for cancer
clearance but without compromising much of the healthy surround-
ing tissues. Clear tumor boundaries are essential for this curative
approach. A novel endoscopic approach integrated with multifunc-
tional GNRs was used by Singh et al., in 2019, as nonconventional
nanotheranostic approach to treat upper gastrointestinal cancer.159
GNRs were functionalized with an optical ﬂuorophore (Cy5.5) modi-
ﬁed with anti-EGFR antibody together with image-guided NIR irra-
diation to enhance cancer site-speciﬁc ﬂuorescence and PTT.
Clinically relevant intravenous GNRs administration route is taken
to overcome the molecular heterogeneity within tumors, and endo-
scopic intravenous injection followed by PTT has induced gastroin-
testinal tumor debulking. When assessing clinical suitability,
nanotheranostics coupled PTT should fulﬁll the criteria of (i) deep
tissue penetration of NIR light, (ii) resistance to photobleaching, (iii)
enzyme degradation, and (iv) high extinction coefﬁcients for effective
light absorption. The nanotheranostics way offered by Singh et al.
are fulﬁlling all these benchmarks as GNRs are resistant to
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photobleaching, enzymatic degradation, and have a 4–6 order higher
extinction coefﬁcient which permits more effective light absorption
than common photosensitizers.
Local ablation, for example, PTT are increasingly employed for
treating nonresectable solid tumors in the liver; this has been clinically
validated on 14 150 colorectal liver metastases (CRLM) patients, strong
survival beneﬁt with a 26.9% and 5 year overall survival achieved for
those undergoing local ablative liver-directed therapies.160 Although
these local ablative PTT have found great potential, they are also lim-
ited by the size and location of tumors and off-target effects such as
bile duct or vascular injury due to the percutaneous insertion and non-
speciﬁc heating by ablative probes. Recently, Parchur et al., from the
Medical College of Wisconsin, United States, developed a PTT device
for tumor-selective interventional radiology-guided liver cancer ther-
apy.161 The primary purpose of this innovation was to demonstrate a
proof of concept for an efﬁcient hepatic site-selective delivery of trimo-
dal optical/MR/X-ray contrast-bearing GNR-based theranostic NPs
(TNPs) by a minor modiﬁcation of the existing interventional image-
guided clinical procedures (Fig. 12). Site-selective delivery of TNPs is
achieved via the hepatic portal vein and PTT using a catheter based
808nm NIR laser. TNPs with a GNR core and inorganic Gd(III) layer
that retain shape and ablative capability over multiple cycles and are
stable in vivo, while providing usable MR and CT contrasts on clinical
scanners for clearly visualizing CRLM tumors.
The combination of “chemotherapyþPTTþ imaging modal-
ities” with different organic therapeutic agents and anticancer drugs
may supportively suppress tumor progression by utilizing the advan-
tages of both modalities and circumventing the drawbacks of each
modality. Novel organic HNCs could be self-assembled into nanodrug
self-delivery systems for combinational cancer nanotheranostics. An
active stealth nanotheranostic strategy was explored by Li et al., by
applying small molecular photothermal agent and chemotherapeutic
drug to construct carrier-free nanomedicines for multimodal imaging-
guided PTT.162 Indocyanine green (ICG) and epirubicin (EPI) are
co-self-assembled into small molecular nanoassembly. Nanoassembly
promoted photothermal response, excellent near-infrared ﬂuorescence
(NIRF) and photoacoustic (PA) dual-modal imaging-guided
synergistic chemo-photothermal therapy (PTT). Furthermore, multi-
functionality of this nanotheranostic system provided real-time self-
monitoring intracellular drug delivery and image-guided synergistic
combination therapy in clinical stage. Several other organic nanoas-
semblies have been proposed in attempts to enhance combinational
FIG. 12. (a) Schematic illustrating the site-selective delivery of TNPs via the hepatic portal vein and PTT using a catheter-based 808 nm NIR laser. (b) Schematic for the syn-
thesis of TNPs along with STEM image demonstrating the morphology of TNPs and Au/Gd elemental mapping. (c) Interventional image-guided TNP delivery and therapy. (i)
3D reconstructions of Dyna CT image of a rat with a CRLM tumor, where the catheter was placed in the liver via a portal vein. Rats were injected with TNPs followed by saline.
DynaCT image of rats (ii) pre-TNPs, (iii) post-TNPs, and (iv) post-PTT. Inset of (i) shows the dark-ﬁeld image of CRLM tumor tissue having TNPs; pointed arrows indicate scat-
tering from TNPs. Reproduced with permission from Parchur et al., ACS Nano 12, 6597 (2018). Copyright 2018 American Chemical Society.161
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chemo-PTT outcomes in preclinical stage, such as nanocolloidosomes
loaded with DOX/ICG,163 methotrexate-hyaluronic acid–octadecyl-
amine-curcumin nanoassembly.164 In contrast to inorganic NPs, NIR
responsive organic NPs bypass the issue of metal-ion induced toxicity
and thus are generally considered to be more biocompatible. Inorganic
NPs possess size-dependent SPR properties, organic NPs have size-
independent optical properties, making it feasible to develop NPs with
the ability of multimodality at different wavelengths with similar bio-
chemical properties. We encourage readers to go through recent
review article, where all optical, chemical, and physical properties of
various organic NPs are introduced, further followed by the discussion
of the PTT and PDT systems.165 Despite a tremendous amount of
exciting different types of NPs and their preclinical results reported in
recent years, however, the further clinic application of PTT is still difﬁ-
cult. The successful combinations of NPs-PTT (NPTT) adjuvant ther-
apy approach and surgery can certify the great potential in clinical
operations in postsurgery or presurgery with prominent features. In
the early 2019, this concept has been validated similar to that of neoad-
juvant chemotherapy; therefore, it is termed as “neoadjuvant
NPTT.”166 Preoperative neoadjuvant NPTT could suppress the breast
tumor in a short time and make the boundary between the tumor tis-
sue and surrounding healthy tissues clearer, therefore creating condi-
tions for better surgical resection. However, this novel light therapy is
more suitable only for some types of superﬁcial tumors at present,
owing to the limited light penetration depth of the NIR laser.
4. Next generation device design
The next generation light activated cancer nanotheranostic strate-
gies seek to maximize the penetration of light, permeability of the drug
to the tumor and therapy using HNCs coupled with biomedical devices
without damaging the healthy environment outside the tumor region.
Catheter-based light guiding systems can transmit the light direct to tis-
sue in this fashion that only diseased tissue can exposed to light. The
novel technology includes a ﬁrst type of catheter conﬁgured for photo-
activating photosensitive materials in tumor and a second type of cathe-
ter conﬁgured for photodegrading photosensitive materials in tissue.167
Likewise, electrospun nanoﬁber device is designed to induce efﬁcient
and repeatable PTT when exposed to an 808nm NIR light without loss
of heating capacity.168 When implanted at the tumor site, this nanode-
vice is making contact with the tumor directly, thus enabling continu-
ous localized PTT and drug release under continuous light exposure.
Advances in optics and ﬁber optical technology resulted in new
generation endoscopes, which offer both diagnostic and therapeutic
capabilities including tissue biopsy and resection of tumors. The new
generation endoscopes not only provide alternatives to surgical resec-
tion but also guide intraprocedural mapping of cancerous tissues, con-
trolling the delivery of NPs for theranostics. Thus, it is possible to
obtain precise information about the location and physicochemical
properties of the targeted growth of tumor or diseased organ.
Researchers from Institute for Basic Science (IBS), Seoul, Republic of
Korea, demonstrated the smart surgical endoscope system as novel
nanotheranostic approach to diagnose and treat colon cancers.169 This
endoscope is conﬁgured with transparent bioelectronics, which pro-
vides impedance- and pH-based sensing, in combination with radio
frequency (RF) ablation therapy to facilitate the characterization and
removal of colon cancers [Fig. 13(a)]. In addition to bioelectronics,
this system has custom-designed biocompatible theranostic NPs with
PTT, PDT, and chemotherapeutic agents, which can be delivered
locally and activated with light. The endoscope allows laser light to
access suspicious sites exposed to NPs. PDT, PTT, and chemothera-
pies induced by nanoassembly containing PDT dyes (chlorin e6; Ce6),
GNRs, Dox, loaded in the mesoporous silica shell, this can effectively
destroy any residual cancer cells around the surgically treated area on
activation with irradiated NIR lasers [Figs. 13(b) and 13(c)]. This
smart endoscope facilitates access to internal tumors and provides a
signiﬁcant amount of diagnostic feedback during treatment routines,
thus highlighting the utility of this technology in the translational
medicine. Kress and colleagues from the Wright State University,
Dayton, USA, have demonstrated light based dual-channel endoscopic
technique for quantitative reﬂectance and ﬂuorescence imaging for
monitoring of local drug concentrations in target areas such as
tumors.170 Importantly, the endoscope serves for light delivery to trig-
ger in vivo drug release in ovarian cancer. This technology demon-
strates the localized NIR-light triggering of chemotherapeutic drug
from nanoliposomes with minimally invasive, quantitative measures
in vivo for fast clinical translation.
C. Two-photon light therapy
1. Underlying physics
At present, one of the main challenges for light activated cancer
nanotheranostics is how to improve the delivery of low-energy pho-
tons of visible/NIR light into deep-seated tumors. Nanomaterials that
absorb light in the phototherapeutic window in a multiphoton fashion
have several advantages for light-triggered therapy and imaging.
Multiphoton absorption causes the materials excitation by two or
more photons, where a single photon is not sufﬁciently energetic; this
novel approach is termed as two-photon absorption (TPA). Moreover,
TPA nanomaterials normally have large two-photon absorption cross
sections, which hold great potential as efﬁcient two-photon donors in
light activated nanotheranostics. The advantages to such an unconven-
tional theranostics approach include (i) higher in-depth light penetra-
tion in tissue since materials are repeatedly triggered by red or near
infrared (NIR) light and (ii) the prospective to selectively stimulate the
material in a physiological medium.171 In particular, NIR two-photon
sensitive nanodevices beneﬁt the three-dimensional resolution and the
low scattering losses of the irradiation in biological tissues, and thus
safer and more selective treatments.
TPA-induced excitation of HNCs (photosensitizers) is a more
promising approach to increase the penetration of light into the tissue.
The development of TPA HNCs can be achieved by the conjugation of
dye molecules onto the nanostructure. The dye molecules simulta-
neously absorb two photons of lower energy to an excited electronic
state (Fig. 14); these excited molecules react with oxygen to generate
singlet oxygen which can be used to induce cell death. When two-
photon dyes are excited in the NIR, light can penetrate deeper into the
tissue as between 800 and 1400 nm, there is minimal absorption and
scattering of light. Indeed, TPA light theranostics combines PDT,
PTT, and tissue ﬂuorescence imaging on the principle of simulta-
neously absorption of two photons with the same energy to the excited
singlet state pass via a virtual intermediary state. New class of HNCs
integrates the advantages of two-photon excitation (TPE) with those
of nanotechnology as novel photosensitizers (PSs). HNCs explore
Applied Physics Reviews REVIEW scitation.org/journal/are
Appl. Phys. Rev. 6, 041306 (2019); doi: 10.1063/1.5049467 6, 041306-21
Published under license by AIP Publishing
FIG. 13. A multifunctional endoscope system. (a) Schematic illustrations of the design strategy and mode of use for the multifunctional endoscope system based on transpar-
ent bioelectronic devices and theranostic nanoparticles. (b) Schematic illustrations of tumor treatment procedures with the multifunctional endoscope. (c) Images of the mouse
model with HT-29 tumors after multimodal treatments (from left to right: control, PDT, PTT, PTTþchemo and combined therapy). Reproduced from Lee et al., Nat. Commun.
6, 10059 (2015). Copyright 2015 Nature Publishing under a Creative Commons Attribution 4.0 International License.169
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basic physical mechanism of PSs via absorbing two lower energy pho-
tons of infrared light, and the sum of the photon energies is equal to
the bandgap of energy. However, one-photon excitation of PSs
requires the absorption of a single photon equal to the bandgap energy
of the PSs. Thus, this novel nanotechnology coupled TPA, thereby
allowing for deeper light penetration and lower photobleaching of PS
molecules in tissues.173 The TPA is a nonlinear photon absorption
process; thus, it makes possible to activate PSs at the focal point of the
laser light, further allowing for better spatial control of PSs activation
in three-dimensions in therapy and imaging, reducing off-target
destruction to surrounding noncancerous tissues during PDT or PTT.
2. Clinical progress
Two-photon excitation is extending the functional window of
NPs by nonlinear excitation mechanism in the NIR region. In the
course of in vivo experiments, TPE is reducing the photobleaching of
NPs and providing a higher spatial image resolution in contrast to
one-photon excitation.174 The next generation TPE nanodevices are
combining diagnosis and image-guided tumor therapy using a single
hybrid PSs and advancing clinical potential of cancer nanophotothera-
nostics. In the year 2006, Gao and co-workers proposed use of NPs as
TPE PSs to treat brain cancer by PDT.175 In this ﬁrst investigation on
such hybrid nanoplatform (according to researcher’s claim), the
encapsulation of polyacrylamide based NPs with dye molecule
TMPyP [5,10,15,20-tetrakis(1-methyl 4-pyridinio) porphyrin tetra(p-
toluenesulfonate)] is performed to evaluate their anticancer efﬁcacy
with and without PDT for rat C6 glioma cells. NIR light excitation of
this HNCs allowed deeper tissue imaging and enabled deeper tissue
two photon PDT while killing glioma cancer cells in vitro. Meanwhile
in the year 2007, Durr and co-workers demonstrated the use of GNRs
as bright contrast agents for two-photon luminescence (TPL) imaging
FIG. 14. Energy diagrams showing one-photon absorption (OPA), two-photon absorption (TPA). Reproduced with permission from Liu et al., Methods Appl. Fluoresc. 5,
012003 (2017). Copyright 2017 IOP Publishing Ltd.172
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of cancer cells in a 3D tissue phantom down to 75lm deep.176 At
760nm excitation light, hybrid GNRs have improved tumor cells
imaging brightness by 3 orders of magnitude compared with two-
photon auto ﬂuorescence emission intensity from unlabeled cancer
cells.
Fortunately, tremendous progress in the present decade on differ-
ent types of HNCs design and development in optical technology pro-
vides an unconventional way to realize TPE in cancer
nanotheranostics by implementing NIR-to-visible conversion pathway
in the tumor. For instance, hybrid gold nanocages with lipid-
hypocrellin B are designed for the TPE combined treatment of PDT
and PTT for ablation of tumor cells in vitro.177 This two-photon acti-
vated nanoassembly (photosensitizer and photothermal transducer)
has minimized the PSs’ negative effect in the unnecessary nontargeted
areas and resulted into results in one-off administration and irradia-
tion for antitumor treatment. Primary in vitro results unlocked new
clinical feature for integration of different approaches to facilitate the
combined treatment. Owing to their collective outstanding properties
such as good biocompatibility, high surface area, large pore volume for
drug storage, broad light absorption, and excellent optical properties
for imaging, carbon dots are widely used as PSs, recently. For example,
hallow ﬂuorescent porous carbon dots loaded with chemotherapeutic
drug can also effectively absorb and convert the NIR light to heat for
regulated drug release and PTT.178 This functional carbon HNCs can
be excited in the higher wavelength region with emission in the lower
wavelength region and acting as optical imaging contrast agent in laser
confocal and two-photon ﬂuorescence cell imaging covering a broad
excitation wavelength range from ultraviolet (UV) light to NIR light.
In the year 2018, Lan and co-workers designed functional carbon dots
with a high ﬂuorescence quantum yield of 49% for integrated platform
of photoacoustic imaging, NIR-triggered two photon phototheranostic
agent for ﬂuorescence imaging, and PTT/PDT synergistic breast can-
cer therapy at clinical stage.179 Several recent studies report various
functional carbon dots for two photon-triggered cancer theranostics
for many types of cancers at clinical stage.180–182 In order to reduce
tumor hypoxia and meet the clinical demands, two-photon light
controlled nano-PSs are developed, including Ru (II) complex loaded
Fe-C3N4 nanocomposite,
183 Bis(pyrene)-Doped Cationic Dipeptide
NPs,184 Dendrimeric NPs,185 hybrid NaGdF4:Yb,Er@NaGdF4:Nd,Yb
UCNPs,186 etc. Most nanophototheranostics modalities proposed
before involve PDT/PTT and NPs that have low photosensitizing efﬁ-
ciencies, tumor resistance, and lack of spatial resolution. On the con-
trary, new generation engineered two-photon-sensitive organosilica
HNCs showing higher photosensitizing yields, versatile therapies, and
a unique spatial resolution. These novel HNCs are effective at clinical
stage in the treatment of retinoblastoma, breast, and skin cancers.187
The growing demand for observation and understanding the
structures and activities of central nervous system (CNS) and CNS
brain tumors, noninvasive brain imaging are highly desirable. Two-
photon activated HNCs with NIR light excitation is novel and rela-
tively noninvasive approach, recently proposed to study brain with
high spatial resolution and large imaging depth. However, clinical
challenges such as cranial window implantation or skull-thinning
methods, attenuation of excitation light, and strong light scattering
induced by skull bone are limiting the use of light-triggered nanothera-
nostic approach in brain cancer. To resolve these issues, Alfu and
co-workers designed HNCs that are conjugating organic dye 2-(4-
bromophenyl)-3-{4-[4-(diphenylamino)styryl]phenyl} fumaronitrile
(TPABDFN) and poly(styrene-co-maleic anhydride) (PSMA).189 This
HNCs have presenting large two-photon absorption cross-section
(5.56 105 GM), and bright NIR emission. Due to the deep penetra-
tion capability of both 1040nm-excitation and NIR emission light, a
very large imaging depth of 1200lm, these HNCs have provided an
effective platform for brain cancer diagnosis. Wang and co-workers in
the early 2019 developed ultrasmall single-chain conjugated polymer
dots (CP dots) that are showing bright NIR-I emission for NIR-II
excited deep in vivo two-photon intact brain imaging.188 In the clinical
stage, these light activated nanoassembly visualized both blood vessels
in the skull bone marrow and brain blood vessels through skull.
Furthermore, 3D reconstruction of the brain blood vessel network
with a vertical depth of 400lm was obtained through intact skull by
using of bright NIR-I emission and NIR-II photoacoustic imaging
(Fig. 15). This next generation nanotheranostics establishes the advan-
tage of two photon excitation in NIR-II and NIR-I ﬂuorescence emis-
sion for deep and high contrast imaging, which provides new
opportunities for noninvasive imaging of brain structures and activi-
ties in neurosciences and neuro-oncology.
D. Future opportunities and challenges
Light activated cancer nanotheranostics is deﬁnitely a promising
new generation treatment modality. Recent advances in biomedical
optics technologies have enabled novel ways of implementing PDT,
PTT, and TPA in targeted cancer therapies. In particular, these modal-
ities are integrating photonics with nanotechnology, biomaterials, and
bioengineering. The heterogeneity of cancerous tumors varies patient
to patient; this disease diversity challenges the chemotherapeutic treat-
ment responses. In recent years’ evident based precision, medicine has
been established next generation cancer therapy in treating diverse
cancerous patients. Among the many approaches to comprehend pre-
cision medicine, the development of light activated nanotheranostic
offerings a realistic personalized line of attack cancer treatment. The
fast development of light-responsive functional HNCs promotes the
research progression in new direction. Remotely triggering of HNCs
by certain wavelength of light can effectively enhances cancer cells
elimination, while preventing the normal tissues from the damage due
to its noninvasive nature further supporting to reduce the side effect.
First, all these light therapies require the use of a pulsed laser light
source to excite HNCs, in general, the very small focal area of the laser
beam is not enough to guarantee the delivery of adequate photo energy
to sensitize NPs. Thus, much longer irradiation of laser light with
accurate positional ﬁne-tuning of the laser beam is required to ensure
adequate photo energy supply to the entire solid tumor. The novel
ﬁber optics technology currently being developed for microendoscopic
phototherapies, e.g., PDT/PTT, advancing the nanotheranostic
approach in clinics with interstitial, endoscopic, intraoperative or
laparoscopic light delivery into tumors.126 Currently using surgical
oncology tools tumors are removed surgically, but there may be many
advantages to irradiate deeper and difﬁcult-to-access tumors using
light-triggered nanotheranostics. The newly introduced wireless video
capsule endoscopes with camera sensor, a light source, a battery, and a
wireless radio frequency transmitter can be considered alternative to
conventional light delivery carriers for diagnosis and therapy of deep
seated tumors.190 Thus, tumors can be treated preoperatively.
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Besides monotherapy, next generation nanotheranostics research
is dedicated to design combined co therapy design instead of mono-
therapy. The recent preclinical investigations and clinical trials demon-
strated that the therapeutic outcome of monotherapy is limited for the
whole tumor elimination and averting cancer metastasis. The mono-
therapy is impartial for heterogeneous, diverse and complex tumors
and just suitable for primary tumors. The synergy effect of PTT/PDT/
chemo is apparent for treating late stage cancer tumors and eliminat-
ing them preoperatively. In this regard, associations of the advantages
of nanotechnology and TPE that hold great promise to selectively
enhance PDT or PTT efﬁciency in deep seated solid tumors. As light-
triggered therapies are pioneered on the concept of phototoxicity,
exploration of NIR light responsive HNCs and photochemistry is
signiﬁcant for future translation. We believe that to achieve 100%
tumor elimination without reoccurrence via PTT/PDT/chemo, a well-
organized NIR light-responsive nanosystem is required. Owing to the
interdisciplinary nature of this ﬁeld, it is vital need of regular accelera-
tions between scientists, academicians, engineers, clinicians, and
FIG. 15. (a) Schematic illustration of NIR-I and NIR-II excited in vivo two-photon excited ﬂuorescence imaging of mouse brain. (b) 3D reconstructed in vivo two-photon excited
ﬂuorescence images of bone, neutrophils, and conjugated polymer dots and their overlay in the bone marrow. (c) 3D reconstructed photon excited ﬂuorescence images of the
brain blood vessels. (i)–(iv) 3D reconstructed image showing the position of the skull and the brain blood vessels network below the skull. Excitation for SHG: 950 nm;
Excitation for 2PF: 1200 nm. Emissions were collected within 455–500 nm for SHG, and 660–750 nm for conjugated polymer dots. Each frame was acquired in 3.22 s.
Reproduced with permission from Wang et al., Adv. Funct. Mater. 29, 1808365 (2019). Copyright 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.188
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industrial reformers. Exchanging the basic scientiﬁc ideas, clinical
knowledge and discussions will advance the next generation cancer
therapeutics and will bring the light-triggered cancer nanotheranostics
to the forefront of oncological diagnosis and intervention. The future
of light responsive nanotheranostics lies in the development of a sole
nanotherapeutic approach that encompasses its applicability in diag-
nosis as well as therapy.
In an attempt to improve diagnosis and treatment for patients
with cancer diseases, few clinical ﬁrms have set up the light activated
cancer treatments. “Theralase” Toronto-based medical device manu-
facturer focuses on the discovery of small light-activated molecules
and the development of laser systems and light activated drug that tar-
get and destroy cancer cells (https://theralase.com/photodynamic).
The Germany based ﬁrm “Biofrontera AG” has advancing the treat-
ment possibilities for nonmelanoma skin cancer with the help of PDT
(https://www.biofrontera.com/en/home-194.html). While on the other
side “CLINUVEL PHARMACEUTICALS” a multinational ﬁrm has
made the remarkable progress in the palliative treatment of advanced
stage cholangiocarcinoma, where a median time survival of 498 days
has been reported in PDT as opposed to 98 days with conventional
therapy (https://www.clinuvel.com/). The current short comings of
light activated medical devices for cancer therapies are unfortunately
undeniable, and therefore there is ongoing effort by scientiﬁc commu-
nity and health industries to develop new technologies and improve
our understanding of how these work in effort to develop not only
more effective, but also more selective, therapies to reduce the burden
on cancer patients.
V. CONCLUSION: THE PROMISE OF PHYSICALLY
STIMULATED CANCER NANOTHERANOSTICS
The potential clinical use of physically stimulated nanotheranos-
tics in cancer treatment has not been thoroughly ampliﬁed. Numerous
small animal preclinical reports are focused on the animal surface or
superﬁcial lesion experiments. A specialized probe for each nanothera-
nostics modality that would stimulate deep seated solid tumors would
be ideal and promising but is technologically challenging in the short
term. Present research directions are focused on designing realistic
theranostics probes that can adequately predict the diagnosis, therapy,
and therapy performance of a wide range of tumors; some of the light
and magnetic probes are discussed in this review. Magnetic and pho-
tonic responsive nanotheranostics have enjoyed growing clinical adop-
tion in many areas, in particular, cancer, and will ﬁnd increasing
utilities in the near future.191,192 Inclusive strategies for designing novel
nanostructures along with enhancing tumor image resolution in con-
junction with conventional radiologic and molecular imaging speciﬁc-
ity make nanotheranostics a powerful next generation modality. In the
years to come, greater than before uniﬁcation of biomedical engineers,
scientists, and clinicians will further enrich the physically stimulated
nanotheranostics in patients. From a technological perspective, real
time implementation of nanotheranostics to patients may not be far
away. In addition to therapeutic approach, it is equally important to
focus on intratumoral NPs loading and chemotherapeutic cargo
release,193 both magnetic and light stimulations currently advancing
the same.
We suggest extending the concept of physical stimulation beyond
its current implication as an individual therapeutic or diagnostic
approach to a comprehensive approach that uses multiple
functionalities to aid or guide nanomedicine measures. As a result of
huge interpatient heterogeneity, personalized cancer nanotheranostics
are desirable for achieving ideal therapeutic efﬁcacy without adverse
side effects. In this regard, magnetic and light stimulation holds great
potential as dual modality on single patient constitutes the whole trial,
recently introduced as “N-of-1” clinical trial.194 On the other side,
instead of chemo-nanotheranostics alone, immune nanotheranostics
in which tumor diagnostics and therapeutics are separately incorpo-
rated195 is a genuine means of cancer diagnosis, patient stratiﬁcation,
and therapy response monitoring. With rapid advances in biomedical
nanotechnologies and ampliﬁed recognition of magneto-plasmonic
versatility in theranostics, many new implantable nanodevices based
on magnetic-light-based functionalities are likely to emerge. It is pro-
jected that nanotheranostic will contribute a signiﬁcant portion of the
more than US$200-billion-per-year global medical device market122 of
personalized implanted medical devices in next couple of years.
A few nanodevices and technologies that operate by the princi-
ples of physical stimulation discussed in this review are undergoing
rigorous clinical trials at present. We need to observe the progress
carefully whether these technologies fulﬁll their potential promise.
New prospects are opening to nanotechnologists and clinicians, with
the success or failure of these technologies, and will be a revealing step
for shaping future cancer theranostics. The review exchanged to date
information on technological development in cancer nanotheranostic
to readers. Readers and scientists working in the nanomedicine ﬁeld
can appreciate that all aspects of magnetic and light stimulation, from
the choice of NPs to stimulation modality, must be thoroughly consid-
ered and tested before clinical translation. However, the clinical trans-
formation of physically stimulated nanotheranostics has been delayed
by several aspects, including NPs strange toxicity proﬁles, biodistribu-
tion, and speciﬁcity of stimulation modality. Despite these and many
other stumbling blocks, we envisage that physically stimulated cancer
nanotheranostics accompanied by chemotherapeutic drugs and radio
imaging modalities will be preferred as an effective therapeutics
approach in the near future.
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